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Therapeutic Drugs in Cancer
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Major Director: Paul Dent, Ph.D.
Vice Chair, Department of Biochemistry

The first study examined the interaction between low doses of the multi-kinase
inhibitor sorafenib and the histone deacetylase inhibitor vorinostat in colon cancer cells.
Sorafenib and vorinostat synergized to kill HCT116 and SW480 cells. In SW480 cells,
sorafenib+vorinostat toxicity correlated with CD95 activation and CD95-stimulated
autophagy. Drug lethality in SW480 cells was blocked by knock down of CD95. In
SW620 cells that are patient matched to SW480 cells, sorafenib+vorinostat toxicity was
significantly reduced that correlated with a lack of CD95 activation and lower expression
of ceramide synthase 6 (LASS6). Overexpression of LASS6 in SW620 cells enhanced
1

2
drug-induced CD95 activation and tumor cell killing, whereas knock down of LASS6 in
SW480 cells suppressed CD95 activation. In HCT116 cells, sorafenib+vorinostat did not
increase CD95 plasma membrane levels, weakly induced caspase 8 association with CD95,
and knock down of CD95 enhanced drug lethality. In HCT116 cells sorafenib+vorinostat
treatment caused CD95-dependent autophagy that was a protective signal. Thus, treatment
of tumor cells with sorafenib+vorinostat activates CD95 that promotes viability via
autophagy or degrades survival via extrinsic or intrinsic pathways. Drug-induced activation
of the de novo ceramide synthesis pathway plays a key role in CD95 activation. The
second project explores the mechanism by which the combination of 17AAG, an hsp90
inhibitor, and PD184352, a MEK1/2 inhibitor alters survival in colon cancer cells. 17AAG
and PD184352 synergized to kill HCT116 and SW480 cells. In HCT116 cells drugexposure increased CD95 plasma membrane levels

In SW620 cells, 17AAG and

PD184352 toxicity was significantly reduced that correlated with a lack of CD95
activation and lower expression LASS6. Overexpression of LASS6 in SW620 cells
enhanced drug-induced CD95 activation and tumor cell killing. In Mia Paca2 cells, a
pancreatic cell line, inhibition of caspase 8 or overexpression of c-FLIP-s suppressed cell
killing by PD184352 and 17AAG exposure.

Drug lethality in Mia Paca2 cells was

blocked by knock down of CD95. Additionally, overexpression of Bcl-xL or knockdown
of caspase 9 decreased cell killing in 17AAG and PD184352 combination treatment. Thus,
17AAG+PD184352 exposure activates the extrinsic and intrinsic apoptotic pathways to
kill Mia Paca2 cells. This document was created in Microsoft Word 2000.
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CHAPTER 1 INTRODUCTION: GENERAL
1.1 Cancer
Cancer is a group of diseases in which cells grow and divide without respect to
normal limits. In other words cancer cells are aggressive, they invade and destroy adjacent
tissues, and they can metastasize, spreading to other locations in the body eventually
leading to death. Benign tumors are not cancerous however. They are limited in their
growth, and do not invade or metastasize. Cancer is caused by external and internal factors
that may act together to promote or initiate carcinogenesis.
tobacco, radiation, chemicals, or infectious agents.

External factors include

Internal factors include genetic

mutations, hormones, or immune conditions 1.
Cancer accounts for nearly one-quarter of deaths in the United States, exceeded
only by heart disease. Lung cancer is the most common fatal cancer in men (31%),
followed by prostate (10%), and colon and rectal (8%). In women, lung (26%), breast
(15%), and colon & rectum (9%) are the leading sites of cancer death 2.
There are various treatments for cancer, each dependent on the type and/or stage of
the cancer. Treatment options include: (1) surgery (removal of the tumor), but this is not
always possible if the cancer has metastasized (2) Radiation therapy (also called
irradiation) in which ionizing radiation is used to kill cancer cells and shrink tumors. The
effects of radiation therapy are localized and confined to the region of the tumor.
Radiation damages the genetic material of a cell. Therefore it also damages healthy cells,
which is the reason why radiation is given in fractions to allow normal cells to recover and

4
function properly. (3) Chemotherapy, the treatment of cancer with drugs that can destroy
cancer cells. This term refers to cytotoxic drugs which affect rapidly dividing cells and are
not specific for cancer cells.

Therefore, chemotherapy can harm healthy tissue. (4)

Combination Therapy, combining drugs that have different modes of action and different
toxicities. An advantage of combination therapy is that it may delay or prevent drug
resistance 1. Even with these current treatments however, more novel therapeutics are
needed to improve patient outcomes.
1.2 Raf/MEK/ERK Mitogen-activated protein kinase (MAP) pathway
Targeted-based therapies are considered to be the future of cancer treatment and
much attention has been focused on the development of inhibitors of the Raf/MEK/ERK
MAP kinase pathway.

The Raf/MEK/ERK MAP kinase pathway is commonly

dysregulated in cancer cells 3-5. There are four well characterized MAPKs. Each cascade
consists of three proteins that act as a relay mainly by phosphorylation signaling. There is
a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK), and a MAPK. The
terminal serine/threonine kinases (MAPKS) comprises, ERK1/2, c-Jun NH2-terminal
kinase (JNK1/2), p38, and ERK5 (Figure 1.1). Activation of the ERK1/2 pathway is often
associated with cell survival, whereas JNK, p38, and ERK5 are activated by stress and
growth factors

6, 7

. Although the mechanisms by which ERK1/2 activation promote

survival are not fully characterized, a number of anti-apoptotic effector proteins have been
identified, including increased expression of anti-apoptotic proteins such as c-FLIP, BclxL, XIAP, and Mcl-1 4, 8-12.

5
In the ERK MAPK module, Ras is a small GTP-binding protein which acts as the
molecular switch that controls this signaling pathway. There are four Ras proteins, namely
H-Ras, N-Ras, Ki-Ras 4A and Ki-Ras4B. Ras is mutationally active in a variety of cancers
and this leads to persistent activation of downstream effectors

13

.

In normal quiescent

cells, Ras is inactivated (GDP-bound). Extracellular stimuli (i.e. EGF), induce the
exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) which
converts Ras into its active conformation.

This process relies on the recruitment of

GDP/GTP exchange factors to the cell membrane. Guanonine nucleotide exchange factors
(GEFs; i.e. Sons of Sevenless, SOS) promote formation of active Ras-GTP whereas; GTP
activating proteins (GAPS) stimulate GTP hydrolysis and formation of inactive Ras-GDP
6

.

Ras activation leads to the recruitment and activation of the MAPKKK (MAP3K), Raf

serine/threonine kinases (c-Raf-1, B-Raf, and A-Raf). Activation of Raf kinases is a
multistep process that involves dephosphorylation of inhibitor sites by protein
phosphatases 2A (PP2A) as well as phosphorylation of activating sites by PAK (p21
activated kinase). The regulatory mechanisms of various isoforms differ in that A-Raf and
C-Raf-1 require additional phosphorylation reactions for activity whereas B-Raf has a
much higher level of basal kinase activity. B-Raf is mutated in over 60% of cancers
making it constitutively active in some types of tumors 6. Raf kinases phosphorylate and
activate MAPKKs, MEK1/2. MEK1/2 then phosphorylates and activates ERK1/2 MAPKs
14, 15

. Active ERKs phosphorylate numerous cytoplasmic and nuclear targets regulating

processes such as proliferation, differentiation, and survival 6(Figure 1.2).
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Figure 1.2. Activation of the Raf/MEK/ERK Mitogen-activated protein kinase
(MAP) pathway. The binding of a growth factor to a growth factor receptor induces
receptor dimerization and autophosphorylation on tyrosine residues. These
phosphotyrosines are docking sites for signaling molecules which include Grb2-SOS
complex. This complex activates the small G-protein Ras by stimulating the exchange of
guanosine diphsophate (GDP) for guanosine triphosphate (GTP). Ras undergoes a
conformational change which enables it to recruit Raf-1 from the cytosol to the cell
membrane and bind to it where Raf-1 becomes active. Activated Raf-1 phosphorylates and
activates MEK1/2 which in turn phosphorylate and activate ERK1/2. Activated ERK may
translocate to the nucleus to control gene expression of transcription factors promoting
growth, differentiation, and development 6, 14, 16.
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1.3 JNK1/2 MAPK Pathway
JNK1/2 pathway signaling often causes apoptosis. JNK activation is much more
complex than that of the ERK1/2 pathway owing to inputs by a greater number of
MAPKKKs

(at least 13, including MEKK1 (MAP/ERK Kinase-Kinase-1)-MEKK4

(MAP/ERK Kinase-Kinase-4), ASK (Apoptosis Signal-regulating Kinase), and MLKs
(Mixed-Lineage Kinases), which are activated by upstream Rho-family GTPases. These
phosphorylate and activate MAPKKs MEK4 (MAPK/ERK Kinase-4) and MEK7
(MAPK/ERK Kinase-7),which further phosphorylate and activate JNKs. JNK activation
requires dual phosphorylation of tyrosine and threonine residues. The JNK family consists
of JNK 1, 2, and 3 (also known as SAPKγ, SAPKα, and SAPKβ, respectively).

JNK 1

and 2 are ubiquitously expressed, whereas JNK 3 is restricted to the brain, heart, and testis
17

.
JNKs (MAPKs) are primarily activated in response to cytokines, UV irradiation,

DNA-damaging agents, growth factor deprivation, and to a lesser extent, serum, and Gprotein coupled receptors. The JNKs are able to translocate to the nucleus following
stimulation. JNKs are generally thought to be involved in inflammation, proliferation and
apoptosis. Accordingly, its substrates are transcription factors and anti-apoptotic proteins.
One well known substrate of JNK is the transcription factor c-Jun. Others include Elk1,
p53, ATF2 (Activating Transcription Factor-2), NFAT4 (Nuclear Factor of Activated TCell-4), and NFAT1 (Nuclear Factor of Activated T-Cell-1) . JNK mediates apoptosis not
only through its effects on gene transcription, but also through a transcriptionalindependent mechanism. For example, JNK1 directly phosphorylates Bcl-2 (B-Cell

9
CLL/Lymphoma-2) in vitro, co-localizes and collaborates with Bcl-2 to mediate prolonged
cell survival. JNK can also phosphorylate the pro-apoptotic protein Bim and Bmf to
promote their pro-apoptotic effects

18

. JNK cascade can also phosphorylate and activate

HSF1 (Heat Shock Factor-1) and JNK-mediated phosphorylation of HSF1 selectively
stabilizes the HSF1 protein and confers protection to cells under conditions of severe
stress 6. Thus, JNKs have opposing roles in promoting proliferation and transformation
and inducing apoptosis.
1.4 p38 MAPK Pathway
In a similar manner to that of the JNK1/2 pathway, the p38 MAPK pathway is
activated by numerous cellular stresses. The p38 module consists of several MAPKKKs,
to include TAK1, ASK1/2, DLK, MEKK1-4, MLK2 and -3, and Tpl-2. The MAPKKKS
phosphorylate and activate MAPKKs, MEK3 and MEK6. These MAPKKs show a high
degree of specificity toward p38 as they do not activate JNK or ERK1/2. MEK4 however,
activates both JNK and p38 and can thus be seen as a site of integration for the p38 and
JNK pathways 6. The MAPKKs phosphorylate and activate the MAPK, p38. There are
four isoforms of p38, α, β, γ, and δ. p38 α and p38β are ubiquitously expressed while p38γ
and p38δ are differentially expressed in certain tissues. All p38 kinases have a dual
phosphorylation sites. MEK6 activates all p38 isoforms, but MEK3 selectively
phosphorylates the p38 α and p38β isoforms 19.
The p38 MAPK pathway has a diverse role in the signaling of cellular responses
that varies with cell type and stimulus. p38 phosphorylates and activates transcription
factors that regulate inflammatory gene expression. A protein kinase termed MAP kinase-
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activated protein kinase 2 (MAPKAP2) is phosphorylated by p38 and is also involved in
many cellular processes including stress and inflammatory responses, nuclear export, gene
expression regulation and cell proliferation. Heat shock protein HSP27 (a chaperone) was
shown to be one of the substrates of this kinase in vivo. Other substrates of p38 include
p53 involved in tumor suppression, and cell cycle regulators such as CDC25A, B, and C.
p38 has also been implicated in other cellular responses such as cell death, development,
and cell differentiation 20.
1.5 PI3-Kinase/Akt Pathway
The phosphatidylinositol 3’-kinase (PI3-K)/ Akt signaling is regarded as a prosurvival pathway in cells.

PI3Ks are a family of intracellular lipid kinases that

phosphorylate the 3’-hydroxyl group of phosphatidylinositols and phosphoinositides.
PI3Ks are heterodimeric kinases that are composed of a regulatory and catalytic subunit
that are encoded by different genes. PI3Ks are classified into three groups, class I, II, and
III based on structure and function 21.
Class I PI3Ks phosphorylate the lipid phosphatidylinositol 4, 5, bisphosphate (PIP2)
to generate the second messenger phosphatidylinositol 3, 4, 5, trisphosphate (PIP3). The
class I PI3Ks are further subdivided according to the signaling receptors that activate them.
Class IA PI3Ks are activated by growth factor receptor tyrosine kinases (RTKs), and class
IIB PI3Ks are activated by G-protein coupled receptors (GPCRs). The regulatory subunit
of class IA is p85 (with three isoforms: p85α, p85β, p55γ). The catalytic subunit of class
IA is p110 (also with three isoforms: α, β, γ). Class IB members consist of a p101
regulatory subunit and a p110γ catalytic subunit

21

.

Class II and class III PI3Ks
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phosphorylate phosphatidylinositol (PI) to generate PI3P. Class II PI3Ks bind clathrin
coated pits and may function in membrane trafficking or receptor internalization

22

.

VPS34 is the only mammalian class III PI3K and acts as a sensor signaling to mammalian
target of rapamycin (mTOR) to regulate cell growth and autophagy in response to low
nutrient pools 23. Class IA however, is the only PI3K class that has been demonstrated to
be clearly involved in oncogenesis 21.
Upon ligand binding to RTKs, RTKs dimerize and autophosphorylate at tyrosine
residues. This allows them to interact with Src homology 2 (SH2) domain containing
molecules. PI3K can be activated by three independent pathways. In one activation
pathway, PI3K p85 regulatory subunit binds directly to tyrosine motifs within the RTK
triggering activation of PI3Ks catalytic subunit. Another pathway consists of the adapter
protein GRB2 which binds preferentially to phosphotyrosine motifs in the RTK. GRB2
can bind to the scaffolding protein GAB (GRB2-asssociated binding protein), which can
bind to p85. GRB2 can also bind to SOS and activate RAS. RAS can activate p110
independently of p85 24. When PI3K is activated it results in the generation of PIP3. 3’phosphoinositide dependent kinase 1 (PDK1) and Akt preferentially bind to PIP3 (by
recruitment to the membrane) which lead to Akt activation depending on its
phosphorylation at Ser473 or Thr308 sites by PDK1. Phosphatase tensin homolog (PTEN)
is a negative regulator of PI3-K pathway that converts PIP3 back to PIP2

21

. Akt (also

known as protein kinase B, PKB) phosphorylates Bad at Ser136 preventing cytochrome c
release. Akt also phosphorylates caspase 9 at Ser196, causing a conformational change

12
that results in the inhibition of its proteolytic activity (Figure 1.3). The overall result is
protection from apoptosis and increased proliferation, events that favor tumorgenesis 25.
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Figure 1.3. Model of PI3K/Akt Pathway Activation. In response to extracellular stimuli
(i.e. growth factors), the catalytic subunit of PI3K (p110) is recruited to receptor tyrosine
kinases (RTKS) at the membrane through its regulator subunit (p85). PI3K phosphorylates
phosphatidylinositol 4, 5, bisphosphate (PIP2) to generate the second messenger
phosphatidylinositol 3, 4, 5, trisphosphate (PIP3). PIP3 recruits serine/threonine Akt and 3phosphoinositide dependent kinase (PDK1) to the membrane. Membrane bound Akt is
rendered fully active through its phosphorylation by PDK1. Activated Akt may
phosphorylate a variety of substrates thereby activating or inhibiting targets important for
cellular growth, survival, and proliferation 24, 25.
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1.6 Apoptosis: Extrinsic and Intrinsic Pathways
There are two well described pathways to initiate apoptosis. One is referred to as
the extrinsic pathway mediated by death receptors on the cell surface, and the other is
identified as the intrinsic pathway, mediated by cytochrome c release from the
mitochondria. Both extrinsic and intrinsic pathways have in common a group of cystine
dependent aspartate specific proteases called procaspases, which require activation to
become full caspases and carry out the cleaving of cellular substrates that result in
biochemical and morphological changes.

Biochemical processes include the

externalization of phosphatidylserine on the cell surface. The morphological changes
during apoptosis include chromatin condensation, cytoplasmic shrinkage, membrane
blebbing, and phagocytosis of the cell or the cell breaks apart forming apoptotic bodies 26.
The extrinsic pathway involves engagement of death receptors that belong to the
tumor necrosis factor receptor (TNF-R) family. Death receptors are activated by their
natural ligands, TNF family. Members of the TNF receptor family share similar cysteine–
rich extracellular domains and have a cytoplasmic domain called the “death domain”.
Death receptors include CD95 (Fas), TRAIL-R1 (APO-2, DR4), TRAIL-R2 (DR5,
KILLER, TRICK2), TNF-R1 (CD120a), and DR3 (APO-3, LARD, TRAMP, WSL1).
Among these receptors, CD95 is the best well characterized death receptor.
Fas is a 45-kDa Type I transmembrane protein, which, like many members of the
TNF/NGF superfamily, contains a number (three in the case of Fas) of cysteine-rich
repeats in its extracellular domain. Such cysteine repeats serve as recognition sites with
respective ligands, and disruption of these repeats leads to the loss of ligand binding and
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effector signaling. The Fas receptor is ubiquitously expressed on a variety of normal cells,
including activated T- and B-cells, hepatocytes, and ovarian epithelial cells, although
regulated expression has been reported in various systems. High levels of Fas expression
have also been detected on solid tumors of the breast, ovary, colon, prostate, and liver. In
contrast, FasL is a Type II cell surface glycoprotein of 40 kDa, which has a cytosolic Nterminus and an extracellular C-terminus. FasL expression is limited, but has been detected
on activated T-cells, natural killer cells, Sertoli cells of the testis, and the corneal
epithelium and the retina of the eye. Some tumors also express FasL, which may be a
mechanism to escape immune surveillance.

Metalloproteinase-mediated shedding of

membrane-bound FasL as a soluble form from effector cells is believed to serve as a
mechanism of turning off apoptosis in bystander cells 27.
Ligation of Fas with FasL (expression of which can be on the same or different
cells) triggers the combination of Fas monomers into trimeric Fas-complexes. Trimer
formation is critical for effector function. The intracellular domain of Fas contains a stretch
of 80 amino acids known as the death domain (DD). DD enables the recruitment and
construction of a multi-protein death-inducing signaling complex (DISC) following Fas
trimerization. DISC formation appears to be required for Fas-mediated apoptosis, as it both
serves as a central relay station to downstream signaling proteins and, more importantly,
provides docking sites for critical effectors in the Fas-death pathway.

Immediately

following Fas/FasL ligation, there is recruitment of the serine-phosphorylated adapter Fasassociated DD (FADD)/MORT1. Fas/FADD interaction is coordinated through the highly
conserved DD motifs found in both proteins. The presence of a functional FADD is
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critical for Fas-mediated apoptosis, whereby the expression of a dominant-negative FADD
completely abrogates Fas-induced cell death. Moreover, in vivo studies revealed a
substantial attenuation of lymphocyte death in mice lacking FADD. FADD serves as a
bridge between Fas and downstream molecules, such as Fas-like interleukin (IL)-1β
converting enzyme (FLICE)/procaspase-8α/β. FADD is a true adapter protein in that it
harbors an N-terminal DD along with a C-terminal death effector domain (DED). Its
unique structure enables FADD to proximally bind Fas on one end, while being able to
distally recruit FLICE on the other

28

. The caspases that are recruited to this death-

inducing signaling complex (DISC) are caspase 8 and caspase 10 which are the initiator
caspases. Once these are activated, caspase 8 can cleave Bid and the intrinsic pathway is
initiated or caspase 8 can directly lead to the activation of executioner caspases (caspase 3,
6, and 7). The active executioner caspases cleave death substrates leading to apoptosis 26.
The intrinsic apoptotic pathway involves non-receptor mediated stimuli that
produce mitochondrial initiated events. Examples include radiation, hypoxia, free radicals,
and hyperthermia. All of these stimuli cause changes in the inner mitochondrial membrane
that result in mitochondria permeability 26. The members of the Bcl-2 family regulate the
intrinsic pathway. Bcl-2 family members are divided into three subfamilies based on their
function and structure: (1) anti-apoptotic proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1/Bfl1,
Boo/Diva, NR-13) that have four BCL-2 homology domains, (2) pro-apoptotic members of
the Bax subfamily that have three BH domains (Bax, Bak, Bok/Mtd) and (3) the BH-3 only
pro-apoptotic proteins (Bik, Bad, Bid, Blk, Hrk, MimL, BNIP3, NOXA, PUMA).

The

BH-3 domain is present in all members and is essential for heterodimerization among
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members and is the minimum domain required for the apoptotic function 29. Activation of
the mitochondria is by the Bcl-2 family member, Bid. Bid is cleaved by active caspase 8
and translocates to the mitochondria. Bid inserts into the membrane and activates Bax and
Bak leading to mitochondrial events that make the membrane permeable for the release of
cytochrome c from the mitochondria.

Cytochrome c binds the apoptotic protease

activating factor 1 (Apaf-1) to form the apoptosome. At the apoptosome, the initiator
caspase 9 is activated. Once the initiator caspase is activated, it cleaves and activates
executioner caspases converging to the final common pathway leading to cell death
30

(Figure 1.4).
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Figure 1.4. The Apoptosis Signaling Pathway. Apoptosis can be initiated by two
pathways, the extrinsic pathway through death receptors or the intrinsic pathway through
the mitochondria. In both pathways, induction of apoptosis leads to the activation of an
initiator caspase (caspase 8 or 10 for the extrinsic pathway, and caspase 9 for the intrinsic
pathway), and activation of executioner caspases, leading to the common pathway of cell
death.
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1.7 Regulation of Apoptosis Signaling
Death receptor mediated apoptosis can be inhibited by a protein named c-FLIP
(FADD-like interlukin-1 β-converting enzyme-like protease). Three splice variants have
been identified in humans. One termed v-FLIP is found only at the mRNA level, whereas
the long form (FLIPL) and a short form (FLIPS) are at the protein level and share structural
homology with procaspase-8, but lack catalytic activity. This structural homology can
allow FLIP to bind to FADD and caspase 8, rendering them ineffective 28.
Anti-apoptotic member, Bcl-2 suppresses cytochrome c release, thereby enhancing
cell survival.

Bcl-xL interacts with Apaf-1 to prevent the activation of executioner

caspases and subsequent apoptosis. Bak is maintained in an inactive state on the surface of
the mitochondria to Mcl-1 or Bcl-xL until an apoptotic stimulus occurs. The depletion of
Mcl-1 in some cells permits Bak oligomerization, activation, and apoptotic cell death 31.
Inhibitor of apoptosis (IAP) proteins directly binds and inhibits caspases 3, 7, and
9. There are eight mammalian members of the IAP family which include, XIAP, c-IAP1,
c-IAP2, NAIP, ILP-2, survivin, bruce, and ML-IAP. There are three proteins that are
negative regulators of IAP proteins, which include, XIAP-associated factor (XAF1),
Second mitochondrial activator of caspases/direct IAP binding protein with low pI
(Smac/DIABLO), and Omi/HtrA2. These proteins can bind to IAPs and abolish their antiapoptotic function. XAF1 accumulates in the nucleus and can sequester XIAP from the
cytosol. Smac/Diablo and Omi/HtrA2 are located in the mitochondria and are released into
the cytosol upon apoptotic stress 32.
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1.8 Autophagy: Function and Process
Autophagy is a process of lysosomal protein degradation in which the cell “eats”
itself. Autophagy serves as an evolutionary conserved survival mechanism in virtually all
cells by providing a way of cells to dispose of damaged organelles and proteins and recycle
molecules for energy. However, it can become deleterious to cells when upregulated and
hence causes cell death, commonly referred to as type II programmed cell death

33

.

Autophagy can be separated into three types, macroautophagy, microautophagy, and
chaperone-mediated autophagy. The focus will be on macroautophagy (hereafter termed
autophagy) because this is the most characterized and well understood form of autophagy
34

.
The first stage of autophagy is vesicle nucleation and begins with a crescent shaped

double membrane vesicle forming that appears in the cytoplasm.

This membrane

continues to elongate, entering the elongation stage, while gathering cytoplasmic cargo
until it closes forming an autophagosome.
constitutes the completion stage.

The formation of the autophagosome

The docking and fusion stage occurs when the

autophagosome targets the lysosome and fuses with it allowing the captured material and
the inner membrane to be degraded (Figure 1.5). The molecular mechanism of autophagy
involves yeast genes termed ATG and its products, Atg. The Atg proteins function at
distinct stages in the autophagy process, of which most have been identified in mammalian
cells as well 33.
The assembly of the preautophagosome (PAS) is referred to as nucleation (Figure
1.6). This step begins with Atg17. Atg17 recruits Atg13 and Atg9, which together
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activate the phosphoinositide 3-kinase (PI3K) class III complex to include Atg14, Atg15,
and vacuolar protein sorting-associated (VPS) 34, or its mammalian counterpart p150.
Atg6, Beclin 1 in mammalians, and UV-irradiation resistance-associated tumor suppressor
gene (UVRAG) also associate with the PI3K complex. Under conditions of nutrient
starvation, Atg13 interacts with Atg1 and the PI3K complex to recruit Atg18 and Atg2.
Atg18 and Atg2 are involved in retrograde transport of Atg9 to the periphery to aid in
membrane recycling 35.
Elongation of the autophagosome is generated by two ubiquitin-like conjugation
systems, Atg12-Atg5 and Atg8-phosphatidylethanolamine (PE). The PI3K complex is
required for the localization of both systems. In addition, both systems are similar to the
ubiquination system, consisting of three enzymes: a ubiquitin-activating enzyme (E1), a
ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase (E3)

36

.

Atg12 is

activated by Atg7 functioning as an E1 enzyme. Atg10 acts as an E2 enzyme, forming a
new thioester bond and Atg7 is released. The last step is the covalent linkage of Atg12 to a
lysine residue of Atg5 and the release of Atg10. This Atg12-Atg5 complex interacts with
Atg16L in mammalians (where Atg16L only binds to Atg5), forming an 800 kDa structure
on the outer membrane necessary for the elongation of the PAS. Once the autophagosome
is complete, this conjugate system dissociates and thus is not a part of the mature
autophagosome

37

. The second ubiquitination system is Atg8-PE. Atg8 is a soluble

cytoplasmic protein that conjugates with PE and becomes attached to the
preautophagosome, as well as the mature autophagosome, and the autophagic bodies. The
mammalian orthologue of Atg8, is microtubule-associated protein 1 light chain 3 (LC3)
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and this protein is one of two credible markers to detect autophagy in mammalian cells.
LC3 is detected in two forms, LC3 I (18 kDa) and LC3 II (16 kDa). LC3 I becomes active
when it is cleaved by Atg4 also known as autophagin. Next, with the catalysis of Atg7 and
Atg3, LC3 I undergo ubiquitination-like reactions and is modified to LC3 II. LC3 II is
tightly bound to the PAS as well as the autophagosome whereas LC3 I is located in the
cytoplasm. Thus, the relative amount of LC3 II reflects the abundance of autophagosomes
present in cells 38. Another marker, p62, also named sequestosome 1 (SQSTM1) is a more
recent protein that may be used to detect autophagy. This protein is a common component
of polyubiquitinated protein aggregates that are degraded by autophagy. The C-terminal
part of p62 contains an ubiquitin-associated (UBA) domain, which binds to ubiquitin
noncovalently. The p62 protein also recognizes LC3 on the autophagosome. Positive p62
structures are degraded via autophagy and this protein can be recognized along with LC3
39

.
After the completion of the mature autophagosome, the next step is the fusion of

the autophagosome with the lysosome. This degrading structure is commonly referred to
as the autolysosome or autophagolysosome 40. There are several factors that are involved
in autophagosome fusion to include the SNARE proteins (i.e. SEC17, SEC18, and YPT7).
Degradation of the autophagosome once fused requires a low pH, proteinase B (PRB1),
and the lipase Atg15.

PRB1 is a hydrolase involved in the activation of vacuolar

zymogens which indirectly affects the vesicle breakdown whereas, Atg15 functions
directly in vesicle breakdown 36.
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1.9 Autophagy: Regulation
There are a number of pathways involved in the regulation of autophagy. A critical
player in autophagy regulation is the mammalian target of rapamycin kinase (mTOR).
mTOR is a serine/threonine kinase that is involved in the control of multiple cellular
processes in response to changes in nutrient conditions 33. It exerts an inhibitory signal on
autophagy, remaining active when the supply of amino acids and other nutrients are ample.
When mTOR is active, it can phosphorylate proteins that are important for cell growth.
mTOR is inactivated when a cell is deprived of nutrients, allowing proteins that are
required for cell survival to be translated. Autophagy is therefore the attempt to provide an
alternate source of nutrients to a cell. Treatment of cells with rapamycin, an inhibitor of
mTOR, blocks cell cycle progression and triggers autophagy. mTOR also appears to affect
Atg proteins, resulting in interference with autophagosome formation. Under nutrient-rich
conditions, activated mTOR causes hyperphosphorylation of Atg13, thereby preventing the
association of Atg13 with Atg1 (Figure 1.6). This step is necessary in the biogenesis of the
PAS.
Another signaling pathway involved in the regulation of autophagy is the PI3K
classes. Evidence that PI3K was involved in autophagy steers from the use of 3methyladenie (3MA), a PI3K inhibitor, that inhibits the autophagy process. Other PI3K
inhibitors (i.e. wortmannin and LY294002) have also been shown to inhibit autophagy 41.
There are three classes of PI3Ks in mammalian cells. Activation of class I PI3K inhibits
autophagy in HT29 colon cancer cells 42. Class II PI3K does not appear to have an effect
on autophagy, however class III PI3K plays a significant role in the early steps of
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autophagy induction as stated previously

35

. In addition, the class III PI3K product,

phosphatidylinositol 3-phosphate (PI3P), stimulates autophagy 42.
1.10 Autophagy and Cancer
Autophagy may play dual roles in cancer progression, providing a mechanism for
cell survival in some tumor cells and cell death in others. One of the players in autophagy,
beclin 1 displays tumor suppressor activity. Consequently, beclin 1 is monoallelically
deleted in 40-75% of human breast, ovarian, and prostate cancers.

Mice with

heterogeneous disruption of beclin 1 are more prone to developing spontaneous tumors and
show a decrease in autophagy 43.

Beclin 1 was originally isolated as a Bcl-2 interacting

protein. Furthermore, Bcl-2 downregulation stimulates autophagy. Consequently, beclin 1
mutations that abolish the interaction with Bcl-2 or Bcl-xL confer a gain-of-function
phenotype with respect to autophagy. Similarly, mutations in Bcl-xL that prevent its
binding to beclin 1 also eliminate its capacity to antagonize autophagy induction. The
autophagy inducing activity of beclin 1 is also inhibited by Mc1-1

44

. PTEN, a tumor

suppressor which dephosphorylates class I PI3K products, prevents autophagy 43. UVRAG
another protein discussed previously as a part of the class III PI3K complex suppresses the
proliferation of human colon cancer cells. However, UVRAG, like beclin 1, is also
monoallelically deleted at a high frequency in human colon cancer cells

45

. Thus,

autophagy signaling is tightly linked to oncogenic signaling. Currently, the variability of
autophagy signaling in cancer cells is the forefront of discussion.
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Figure 1.5. The Cellular Aspect of Autophagy. The cellular process of autophagy
follows distinct stages: vesicle nucleation (formation of the isolation membrane), vesicle
elongation (growth of the membrane from the preautophagosomal structure to the mature
autophagosome), docking and fusion of the autophagosome with the lysosome to form an
autolysosome, and lastly breakdown of the autolysome and the degradation of its contents.
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Figure 1.6. The Molecular Aspect of Mammalian Autophagy. The first regulatory
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When mTor is inhibited as in starvation conditions, hypophosphorylated Atg13 forms a
complex with Atg1 and Atg17, inducing autophagy. Starvation conditions also activate
class III phophatidylinositol 3-kinase (PI3K) which activates the PI3K complex leading to
vesicle nucleation. The PI3K complex consists of Atg14, Atg15, and a myristylated kinase
named p150. The formation and activity of this complex also depends on its binding to
Beclin 1 and UV irradiation resistance-associated tumor suppressor gene (UVRAG).
Vesicle elongation begins with two ubiquitin-like conjugation systems. One system
involves the conjugation of Atg12 and Atg5 by the E1 like enzyme Atg7 and the E2 like
enzyme Atg10.
The second pathway involves the conjugation of LC3 and
phosphatidylethanolamine (PE) by the protease Atg4 and the E1 enzyme Atg7 and the E2
enzyme Atg3. This conjugation leads to the conversion of the soluble form LC3 I to the
autophagic vesicle form LC3 II. The retrieval of essential amino acids is through the
association of Atg18 with Atg9, however this mechanism is poorly understood. Shown
above are the complexes that have been identified in mammalian cells, with the exception
of Atg13 and Atg17 that have only been identified in yeast.
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1.11 ER Stress: The Unfolded Protein Response
The endoplasmic reticulum (ER) is the site of biosynthesis of proteins targeted for
membranes or secreted from the cell. The ER is a membranous network throughout the
cytoplasm of eukaryotic cells that folds, assembles, and glycosylates these proteins.
Homeostasis within the ER is important for proper protein folding, thus to prevent the
accumulation of unfolded proteins, the ER activates the unfolded protein response
(UPR)46.

UPR allows for an increase in the degradation of misfolded proteins, the

reduction in newly translated proteins entering the ER, and an increase in the capacity of
protein folding. If the stress on the cells is too much, the UPR signals for the cells to
undergo cell death in order to preserve the surrounding cells.
There are three primary UPR sensors, protein kinase-like ER kinase (PERK),
activating transcription factor 6 (ATF6), and IRE1 (Figure 1.7).

There are several

chaperones which aid in proper proteins folding including binding lg protein (BiP). BiP, is
also known as glucose regulated protein 78 (GRP78), and is a member of the heat shock
protein 70 family 46. Bip is bound to the luminal domains of the three UPR sensors under
normal conditions. When there is an increase in unfolded proteins within the ER, Bip will
preferentially bind to the misfolded proteins, and dissociates from PERK, ATF6, or IRE1
leaving these proteins free to perform their functions. One sense stressor, IRE1, is an ER
transmembrane protein kinase endoribonuclease that dimerizes (alpha and beta subunits)
upon dissociation from Bip activating its cytosolic RNase domain. Its RNase activity
cleaves an X box DNA binding sequence.

The resulting XBP1 migrates to the nucleus

and binds the upstream DNA UPR element, and thus is a potent activator of UPR genes
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that are essential for protein folding, migration, and degradation. ATF6, upon release form
Bip, travels to the Golgi where it is cleaved by site 1 and site 2 proteases (S1P and S2P).
This now active form of ATF6 migrates to the nucleus and binds to the ER stress response
elements (ERSE) to promote the transcription of ER-resident chaperones and other
assistant folding enzymes. When the third UPR sensor, PERK, is dissociated from Bip, it
homodimerizes, autophosphorylates, and phosphorylates the alpha subunit of eukaryotic
translation initiation factor 2 (eif2α) at serine 51 46. Eif2α is required to bring the initiator
methionyl-transfer RNA (Met-tRNAi) to the 40S ribosome.

Thus, when eif2α is

phosphorylated, it can no longer exchange GDP for GTP and this prevents the 40S
ribosome and the 60S ribosomal unit from forming the 80S initiation complex necessary
for translation. However, activating transcription factor 4 (ATF4) is translated after eif2α
is phosphorylated and activates genes involved in amino acid metabolism, transport,
oxidative-reduction reactions, and ER stress-induced apoptosis. One of these proteins,
C/EBP homologous transcription factor (CHOP) is implicated in both growth arrest and
cellular apoptosis. Thus with prolonged UPR activation, ATF4 can induce expression of
CHOP leading to caspase 3 activation and apoptosis 47.
Before a cell commits itself to apoptosis due to prolonged UPR activation, a cell
coordinates itself with the ER associated degradation (ERAD) system. This system allows
the misfolded proteins to be degraded. XBP1 is responsible for increasing expression of
genes encoding proteins required for ERAD. Alternatively, under prolonged UPR, ER
calcium homeostasis is significantly disrupted, leading to activation of caspase 12 (in mice
only).

The human caspase-12 gene however, contains several missense mutations and

29
clearly cannot have a role in UPR-induced apoptosis. Recent data indicates that caspase 4
in humans is homologous to murine caspase12

48

activation of caspase 9 and 3, leading to apoptosis.

. Caspase 12/4 activation leads to the
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Figure 1.7. The Unfolded Protein Response. Upon accumulation of misfolded or
unfolded proteins in the ER lumen, Bip/Grp78 dissociates from UPR sensors PERK, IRE1
and ATF6. Bip/Grp78 release from PERK results in PERK’s dimerization and
autophosphorylation. Activated PERK phosphorylates eif2α, inhibiting translation and
resulting in cell cycle arrest. However, selective mRNAs such as ATF4 can be
preferentially translated by the phosphorylated eif2α. Bip/Grp78 release from IRE1
permits its dimerization and activates its kinase and RNase activities to cleave an X box
DNA binding sequence, to form the transcription factor XBP1. XBP1 translocates to the
nucleus and binds to the upstream DNA UPR element. Paradoxically, Bip/Grp78 release
from ATF6, activates ATF6 and allows it to translocate to the Golgi where it is cleaved by
site 1 and site 2 (S1 and S2) proteases to form an active 50kDa fragment (ATF6 p50). This
fragment migrates to the nucleus and binds to the ER stress response elements (ERSE) to
activate transcription of UPR responsive genes. Additionally, calcium homeostasis is
disrupted leading to the activation of caspase 4 (or caspase 12 in rodents), thus signaling an
ER dependent apoptotic response. Caspase 2 cleaves Bid in response to ER stress, leading
to caspase 9 activation and apoptosis.
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1.12 Ceramide
Long chain sphingoid bases are the defining feature of sphingolipids. Ceramide is a
spingosine-based lipid signaling molecule that regulates differentiation, proliferation, and
apoptosis.

Ceramide has attracted great attention due to its emerging role as an

intracellular effector molecule in apoptosis. Several environmental stresses shown to
initiate apoptosis, such as ionizing radiation, induce rapid ceramide generation

49

.

Ceramide is one of the most hydrophobic molecules in mammalian cells. It can be
synthesized de novo (anabolism) or by sphingomyelinase (SMase)-dependent catabolism
of sphingomyelin (SM) (Figure 1.8).
De novo synthesis begins by condensation of serine and palmitoyl-CoA to form
ketosphinganine, which is then reduced to dihydrosphingosine.

The acylation of

dihydrosphingosine to dihydroceramide is catalyzed by ceramide synthase (sphinganine Nacyl transferase)

50

. It is now known that there are six mammalian genes that encode

dihydroceramide synthase and they are termed longevity-assurance homologues (LASS1LASS6). These ceramide synthases show distinct preferences for the different fatty acylCoA substrates and therefore generate distinct ceramides with different acyl-chain lengths
51

. Dihydroceramide reductase catalyzes the oxidation of dihydroceramide to form the

trans-4,5, double bond of ceramide. Dihydroceramide is generated in the endoplasmic
reticulum as well as the mitochondria 50.
The catabolic pathway for ceramide involves the action of sphingomyelinases and
sphingomyelin-specific forms of phospholipase C, which hydrolyzes the phosphodiester
bond of sphingomyelin (N-acylsphingosin-1-phosphorylcholine; SM). Sphingomyelin is a
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phospholipid preferentially found in the plasma membrane of mammalian cells that yields
ceramide and phosphorylcholine

50

. There are various isoforms of sphingomyelinases

which are distinguished by their pH. A-SMase is the acidic sphingomyelinases located in
acidic compartments such as lysosomes or endosomes. N-SMase (neutral) operates at the
plasma membrane

52

.

Ceramide can also be generated by breakdown of complex

glycosphingolipids through acid hydrolases referred to as the salvage pathway 51. Most of
the ceramide required for the production of complex lipids is synthesized in the
endoplasmic reticulum (ER), with subsequent metabolism occurring in the Golgi
apparatus. A cytoplasmic ceramide transporter or 'CERT', mediates the transport of
ceramide between the ER and the Golgi in a non-vesicular manner. It has a
phosphatidylinositol-4-monophosphate-binding domain, which targets the Golgi apparatus,
and a short peptide motif that recognizes a specific protein in the endoplasmic reticulum.
The CERT protein extracts ceramides only from membrane bilayers with some specificity
for those containing C14 to C20 fatty acids, and delivers it for the synthesis of
sphingomyelin but not for glycosylceramide. The pool of ceramide utilized for synthesis of
the glycosylceramide is delivered to the Golgi by a vesicular transport mechanism 51
The physical properties of ceramides ensure that they are concentrated
preferentially into lateral microdomains (rafts) with other sphingolipids, especially
sphingomyelin. Ceramides may be generated within these rafts by the action of
sphingomyelinases, causing small rafts to merge into larger units and modifying the
membrane structure in a manner that is believed to permit oligomerization of specific
proteins (i.e. integrins). Through the medium of rafts, they are then able to function in
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signal transduction. Specific receptor molecules and signaling proteins cluster within such
domains 53.
Once generated, ceramide can accumulate in the cell or be converted into a variety
of metabolites. Ceramide can be converted to ceramide-1-phosphate by ceramide kinase
and to SM by transfer of phosphorylcholine from phosphatidylcholine to ceramide by the
enzyme SM synthase. Additionally, ceramide can be glycosylated by glucosylceramide
synthase in the Golgi apparatus. Ceramide can also be deacylated by either neutral or acid
ceramidases to yield sphingosine, which then may be further phosphorylated to
sphingosine-1-phosphapate (S1P) by sphingosine kinase. Thus, ceramide generated under
multiple metabolic pathways may act differently in response to different stimuli. 49.
There is the existence of a “SIP Rheostat” that may explain how ceramide can
have a variety of diverse functions. This proposal is based on the fact that ceramide and its
metabolite S1P can have opposing effects. Ceramide is usually considered pro-death and
anit-proliferative while S1P promotes survival and cellular proliferation

54

. Ceramide

plays a leading role in apoptotic signaling, including death receptor mediated TNF-α and
CD95 cell death. After stimulation through these death receptors, the intracellular adapter
FADD is required to activate A-SMase which then causes ceramide production and
activation of caspases as well as p38 and JNK MAPKs 49. S1P has also been implicated in
protection against ceramide-induced cell death

55

Thus, the cell is destined for cell death

when the balance leans towards ceramide and sphingosine, and towards cell survival and
proliferation when S1P levels are increased 54.
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Figure 1.8. Ceramide Synthesis 51. The main pathways to ceramide generation include
the de novo pathway, the sphingomyelinase pathway, and the salvage pathway.
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1.13 Molecular Chaperones in Protein Folding
Protein folding is the physical process by which a polypeptide folds into its
characteristic three-dimensional structure. Protein structure can be described at four levels.
The primary structure consists of the amino acid sequence and this determines the threedimensional structure. The secondary structure refers to the polypeptide chain folding into
a regular structure (i.e. alpha helix, beta sheet, and turns and loops). The tertiary structure
is the compact, asymmetric structure in which all proteins have the common features of
interior amino acids with a hydrophobic side chain and hydrophilic amino acids that can
interact with the aqueous environment. The quaternary structure refers to the assembly of
multisubunit structures. The correct structure of the protein is essential for its function.
Thus, incorrect folding usually produces inactive proteins. The process of folding in vivo
beings co-translationally so that the protein’s N-terminus begins to fold while the Cterminus is still being synthesized on the ribosome 56.
Molecular chaperones also known as heat shock proteins (hsps) are ubiquitous in
nature and act to maintain proper protein folding within the cell or proteasome-mediated
degradation in the case of damaged proteins 56. These proteins facilitate the correct folding
in vivo but they do not contain steric information regarding the correct folding. Instead,
they prevent incorrect interactions within non-native polypeptides increasing the yield but
not the rate of folding reactions 56. The demand of these heat shock proteins increases after
environmental stress (i.e. drugs, toxic chemicals, and extreme temperatures), non-stress
conditions, and disease states (i.e. Alzheimer’s disease and cystic fibrosis) 57.
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Hsps are classified by molecular weight into six major hsp families to include the
small hsps (20-25 kda), hsp40, hsp60, hsp70, hsp90, and hsp100 58. The small hsps bind to
partially denatured proteins and are responsible for protecting proteins from irreversible
aggregation via an energy-independent process. Once suitable conditions are obtained for
renewed cellular function, protein release and refolding are mediated by ATP-dependent
chaperones like hsp70

59

. The small hsps also function to maintain the integrity of

membranes via specific lipid interactions under physiological conditions 60. Hsp40, hsp60,
and hsp70 are all involved in nascent protein folding 56. Additionally, hsp40 is considered
a co-chaperone for hsp70, playing a vital role in the stimulation of conformational changes
in the ATPase domain of hsp70

61

.

Hsp70 is also important in the degradation of

misfolded proteins as well as stabilization processes 56. The hsp100 family of chaperones,
function to disaggregate proteins and some members of this family target specific classes
of proteins for degradation

62

. Hsp90 however, seems to be more important in cancer

progression, stabilizing a number of signaling proteins involved in cancer progression and
is it not required for de novo protein synthesis 63.
1.14 Hsp90 Structure and Function
Hsp90 is a heat shock protein that conserves the folding of newly translated protein
64

.

It is distinctly different from other chaperones in that most of its substrates are

signaling proteins. Classic examples include steroid hormone receptors and signaling
kinases 65, 66. Thus, disruption of Hsp90 in tumor cells has been shown to induce improper
folding of many proteins, including Raf-1, B-Raf, Akt, and ERBB family receptors
culminating in their proteosomal degradation

67

. Hsp90 is a constitutive homodimer and
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has 3 domains, a 25 kda N-terminal domain, a charged linker domain, and a 55 kda Cterminal domain. The N-terminal domain binds ATP and other purine analogues 68, while
the C-terminal domain is responsible for dimerization and is required for biologic activity
69, 70

. Hsp90 consists of two isoforms, alpha and beta. Hsp90α is elevated under stress

conditions whereas hsp90β is constitutively expressed. The proteins are encoded on two
separate genes, chromosome 14 for Hsp90α and chromosome 6 for hsp90β

71

. Although

there are some functional differences between the two the isoforms 72 they are usually not
distinguished from each other

73

.

However, a knockout mouse strain for hsp90β is

embryonic lethal 74.
The activity of hsp90 depends on an organized series of conformational changes
and interactions with co-chaperones and client proteins operating in an ATP dependent
cycle. There are over one hundred client proteins many being signal transduction proteins
75

. The interaction between hsp90 and many of its co-chaperones occur within the C-

terminal domain of hsp90 76. The extreme C- terminus contains the amino acid sequence
MEEVD, which is the binding site for co-chaperones that contain the tetratricopeptide
repeat (TPR) region

77

.

The biochemical mechanism of hsp90 binding to its client

proteins involve ADP-bound hsp90 binding to hsp70 through accessory proteins like Hip
and Hop. Hop has a TPR domain and binds to the C-terminus of hsp90. Hop also binds
the N-terminal region of hsp70 thus linking hsp90 to hsp70 76. The binding of Hop induces
a conformational change in the ATPase domain of hsp90 that inhibits the ATPase activity
68

.

Dissociation of Hop and hsp70 results in another conformational change in the

ATPase domain that enables ATP to bind. Upon this ATP binding, the N-terminal regions

38
transiently dimerize while the C-terminal domains remain dimerized and a molecular
clamp is formed around the client protein

78

. Mature complexes of hsp90 with bound

substrate (client proteins) are also characterized by binding of the co-chaperone p23. p23
stimulates the ATP hydrolysis and opening of the molecular clamp formed which causes
dissociation of the hsp90-substrate complex. Thus the hsp90substrate binding and release
cycle is regulated by Hop and p23

78

. Hsp90-bound proteins can also be targeted for

degradation by the co-chaperone CHIP. This protein has a TPR domain that recognizes
both hsp90 and hsp70. CHIP contains a U-box domain similar to the E4 ubiquination
proteins and may function to present misfolded proteins for ubiquination 79.
1.15 Hsp90 Regulation: Heat Shock Factors
Hsp90 genes are regulated by a family of transcription factors known as heat shock
factors (HSFs). Hsp90 genes contain heat shock-responsive elements in their promoters,
which are bound by the HSFs to initiate transcription. There are 4 HSF proteins to include
HSF1, 2, and 4 which are ubiquitous in nature, and HSF3 which has been characterized in
avain species 57. Of the HSFs, HSF1 is the principal stress-induced transcription factor 80.
Mice lacking HSF1 can develop normally and reach adulthood. However, fibroblasts from
these deficient mice are incapable of stress-induced transcription of heat shock genes 81.
HSFs consist of four conserved structural domains. The DNA binding domain is
characterized by a helix-turn-helix motif. There is also a hydrophobic repeat domain
essential for trimer formation and a carboxy-terminal transactivation domain

82

. Under

unstressed conditions, HSF1 exists as a cytosolic monomer in complexes containing hsp70
and hsp90. Upon exposure to stress, HSF1 is activated and binds to the heat shock
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promoter element (HSE) in hsp promoters. HSF1 forms a phosphorylated homotrimer in
the nucleus that activates a program of transcription, including the upregulation of HSP
production 83.
The transcriptional regulation of HSF1 is controlled in part by heat shock proteins.
It has been shown that the binding of hsp70 to HSF1 at the hydrophobic carboxy-terminus
suppresses the function of HSF1. When there is accumulation of non-native proteins
during a stressful event, these may compete with HSF1 for binding to chaperone hsp70.
Unbound HSF1 could then homotrimerize and be available for transcription 84. Similarly,
hsp90 can form a complex with HSF1 and repress its function as well. Additionally,
geldanamycin, an inhibitor of hsp90, activates HSF1 in vitro 85.
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CHAPTER 2 INTRODUCTION: SORAFENIB AND VORINOSTAT
2.1 Colon Cancer
Colorectal cancer is cancer of the colon or the rectum. The colon and the rectum
are part of the digestive system, normally referred to as the gastrointestinal or GI system.
Before colon cancer develops, benign polyps (abnormal masses of tissue) begin growing
on the inner lining of the colon or rectum. These growths spread very slowly, taking from
10 - 20 years to become cancerous. Colonic polyps are divided into 3 groups, hyperplastic
polyps, adenomas, and polyposis syndromes. Hyperplastic polyps comprise about 90% of
all polyps and are benign protrusions.

This type of polyp is usually insignificant.

Adenomas comprise approximately 10% of polyps and pose a risk of becoming invasive.
The risk of progression to carcinoma though, is related to both the size and the histology of
the adenoma.

Polyposis syndromes are hereditary conditions which may lead to an

increased risk of developing colon cancer. Once colorectal cancer is diagnosed, the
prognosis depends on how far the cancer has spread 86.
Colon cancer is the third most commonly diagnosed cancer among men and women
in the United States. Each year more than 50,000 patients die from colorectal cancer with
a 5 year survival rate of ~60%. However, for patients with non-localized tumor at
diagnosis, the 5 year survival is ~10% 2. These statistics indicate the need to develop new
therapies to combat this type of cancer.
2.2 Colon Cancer Resistance
There are two main inherited predisposition syndromes for colorectal cancer:
hereditary non-polyposis colorectal cancer (HNPCC) and familial adenomatous polyposis
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(FAP).

One reason for resistance may be related to genetics, for example chromosomal

instability since colon cancer has a predisposition. A significant obstacle for successful
management of patients with colorectal cancer is intrinsic drug resistance or, in patients
who initially responded to chemotherapy, acquired drug resistance. Failures in normal
apoptotic pathways contribute to resistance against anti-cancer drugs or radiotherapy. Also
resistance generally is observed from cancers that arise from tissues that have detoxifying
functions (i.e. colon, stomach, and kidney). It is thought that tissue-specific detoxification
mechanisms are operative in the cancer cells and protect them from chemotherapy. Most
improvements in the advancement of colon cancer stems from the use of drug
combinations 87.
2.3 Sorafenib
In view of the importance of the RAF-MEK1/2-ERK1/2 pathway in neoplastic cell
survival, inhibitors have been developed that have entered clinical trials, including
sorafenib (Bay 43-9006, Nexavar®; a Raf kinase inhibitor).

Sorafenib is an orally

available bi-aryl urea compound (Figure 2.1). Sorafenib is marketed as Nexavar by Bayer
and it is approved for the treatment of advanced renal cell carcinoma. It was originally
developed as a small molecular inhibitor of Raf kinase (to include C-Raf, B-Raf, and
mutant B-Raf or V599E), a member of the MAP kinase pathway. However, it is shown to
also inhibit proteins involved in tumor angiogenesis. Sorafenib inhibits class III tyrosine
kinase receptors such as platelet-derived growth factor (PDGFR-β), vascular endothelial
growth factor receptors 2 and 3 (VEGFR-2, VEGFR-3), c-kit, and Flt-3 tyrosine kinases 88.
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Thus, sorafenib has the potential to prevent tumor growth by combining two anticancer
activities: inhibition of both tumor cell proliferation and tumor angiogenesis (Table 2.1).
Sorafenib has undergone numerous Phase 1 evaluation trials in refractory solid
tumors. In 2000, Phase 1 trials showed the optimum regimen to be 400 mg b.i.d. orally.
All four trials identified a hand-foot skin reaction as the most prominent dose-limiting
toxicity

89

. Sorafenib is metabolized by oxidative metabolism mediated by cytochrome

P450 (CYP) 3A4 and glucoronidation mediated by UGT1A9. The main metabolite of
sorafenib is pyridine N-oxide. The intake of food does not impact sorafenib metabolism
but a high fat meal does reduce bioavailability by 29%, although the label recommendation
is that sorafenib be taken with food

90

. Anti-tumor effects of sorafenib in renal cell

carcinoma and in hepatoma have been ascribed to anti-angiogenic actions of this agent
through inhibition of the growth factor receptors 90-92. Several groups, including ours, have
shown in vitro that sorafenib kills human leukemia cells at concentrations below the
maximum achievable dose (Cmax) of 15-20 µM, through a mechanism involving downregulation of the anti-apoptotic Bcl-2 family member Mcl-1

93, 94

. In these studies

sorafenib-mediated Mcl-1 down-regulation occurred through a translational rather than a
transcriptional or post-translational process that was mediated by endoplasmic reticulum
(ER) stress signaling 95, 96. This suggests that the previously observed anti-tumor effects of
sorafenib are mediated by a combination of inhibition of Raf family kinases and the
ERK1/2 pathway; receptor tyrosine kinases that signal angiogenesis; and the induction of
ER stress signaling.
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2.4 Vorinsotat
Vorinostat or suberoylanilide hydroxamic acid (SAHA), marketed as Zolinza, is a
histone deactylase inhibitor (Figure 2.2). Histone deacetylase inhibitors (HDACI) represent
a class of agents that act by blocking histone de-acetylation, thereby modifying chromatin
structure and gene transcription. HDACs, along with histone acetyl-transferases,
reciprocally regulate the acetylation status of the positively charged NH2-terminal histone
tails of nucleosomes. HDACIs promote histone acetylation and neutralization of positively
charged lysine residues on histone tails, allowing chromatin to assume a more open
conformation, which favors transcription 97. However, HDACIs also induce acetylation of
other non-histone targets (Figure 2.3), actions that may have plieotropic biological
consequences, including inhibition of HSP90 function, induction of oxidative injury and
up-regulation of death receptor expression 98-100. Vorinostat inhibits the enzymatic activity
of HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar
concentrations. Vorinostat inhibits HDACs by binding to a zinc ion in the catalytic
domain of the enzyme

101

. Vorinostat has shown preliminary pre-clinical evidence of

activity in hepatoma and other malignancies with a Cmax of ~9 μM 102-104.
Vorinostat is the first new HDACI to be approved for clinical use by the food and
drug administration
(CTCL).

105

. It is used for the treatment of cutaneuous T cell lymphoma

The recommended dose for vorinostat is 400 mg orally once daily with food.

The major dose-limiting toxicities associated with oral vorinostat were observed in phase 1
and 2 clinical trials and included anorexia, dehydration, diarrhea, and fatigue.

The major

pathways of vorinostat metabolism involve glucoronidation and hydrolysis followed by β-
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oxidation.

There are two pharmacologically inactive metabolites, O-glucoronide of

vorinostat and 4-anilino-4oxobutanoic acid that are formed 106.
2.5 Basis for Sorafenib and Vorinostat Project
With respect to combinatorial drug studies with a multi-kinase inhibitor such as
sorafenib, HDACIs are of interest in that they have potential to down-regulate multiple
oncogenic kinases by interfering with HSP90 function, leading to proteasomal degradation
of these proteins. Thus, if we combine sorafenib and vorinostat, this combination may
prove to be more effective than individual drug alone. Additionally, lower does of these
agents could be given to achieve the same toxic effects individually.

We recently

published that sorafenib and vorinostat to interact to kill in renal, hepatocellular and
pancreatic carcinoma cells via activation of the CD95 extrinsic apoptotic pathway,
concomitant with drug-induced reduced expression of c-FLIP-s via PKR like endoplasmic
reticulum kinase (PERK) signaling to eIF2α

107, 108

. Subsequent work mechanistically

advanced our understanding to reveal that sorafenib and vorinostat interact by activating
acidic sphingomyelinase and the de novo ceramide pathway to promote CD95 activation
which regulates both apoptosis and autophagy 108. The present studies determined whether
the same killing mechanisms apply after sorafenib and vorinostat treatment in colon cancer
cells.
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Sorafenib (BAY 43-9006)

Figure 2.1. Chemical Structure of Sorafenib 109.
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Biochemical Assay *
Raf-1 **
BRAF wild-type
V599E BRAF mutant
VEGFR-2
mVEGFR-2 (flk-ss1)
mVEGR-3
mPDGFR-β
Flt-3
c-KIT
FGFR-1
ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-met,
PKB, PKA, cdk1/cyclinB, PKC, PKC, pim-1

IC50 (nM) ± SD
6±3
22 ± 6
38 ± 9
90 ± 15
15 ± 6
20 ± 6
57 ± 20
58 ± 20
68 ± 21
580 ± 100
>10,000

Table 2.1. Sorafenib inhibition of the MAP Kinase pathway and receptor tyrosine
kinases involved in tumor angiogenesis. * Kinase assays were carried out at ATP
concentrations at or below Km (1-10 µM)** Lck-activated NH2-terminal-truncated Raf-1.
(Adapted from 110.)
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Figure 2.2. Chemical Structure of Vorinostat 111.
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Figure 2.3. HDACI complex mechanism of action 112.

CHAPTER 3 MATERIALS AND METHODS: SORAFENIB AND
VORINOSTAT
3.1 Materials
Dulbecco’s Modified Eagle’s Medium (DMEM), RPMI 1640 medium, trypsinEDTA, and penicillin-streptomycin were purchased from GIBCOBRL (GIBCOBRL Life
Technologies, Grand Island, NY). Trypan blue solution, formaldehyde, 6-Diamidino-2Phenylidole (DAPI), and dimethyl sulfoxide (DMSO) were all obtained from Sigma
Chemical (St. Louis, MO).
Sorafenib (BAY-439006; Bayer) and vorinostat (Merck) were provided by the
Cancer Treatment and Evaluation Program, National Cancer Institute/NIH (Bethesda,
MD). Obatoclax was generously provided Gemin X Biotechnologies. JNK inhibitor
peptide was supplied by Calbiochem (San Diego, CA) as a powder, dissolved in sterile
DMSO, and stored frozen under light-protected conditions at -80˚C.
Anti-caspase 3 (1719//35 kDa cleaved/full, 1:1000, rabbit monoclonal), Anticaspase 8 (18/43/57 kDa cleaved/full, 1:1000, mouse monoclonal), Anti-FLIP (30/60 kDa
short/long, 1:1000, rabbit polyclonal), anti-Beclin-1 (60 kDa, 1:1000, rabbit polyclonal),
anti-Mcl-1 (40 kDa, 1:1000, rabbit polyclonal), phospho-eIF2α (38 kDa, 1:1000, rabbit
polyclonal), phospho-/total-p38α/β (38 kDa, 1:1000, rabbit polyclonal), phospho-/totalJNK1/2 (46, 54 kDa, 1:1000, rabbit polyclonal), anti-Bcl-2 (26 kDa, 1:500, mouse
monoclonal), anti-Bcl-xL (30 kDa, 1:1000, rabbit polyclonal), anti-BID (15/22 kDa
cleaved/full, 1:1000, rabbit polyclonal), anti-Bip (78 kDa, 1:1000, rabbit polyclonal), anti49
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FAS receptor (48 kDa, 1:1000, rabbit polyclonal), anti-FAS ligand (40 kDa, 1:1000, rabbit
polyclonal), anti-Bak (25 kDa, 1:1000, rabbit polyclonal) and anti-Bax (20 kDa, 1:1000,
rabbit polyclonal) were obtained from Cell Signaling Technology ( Worcester, MA). AntiGAPDH (37 kDa, 1:1000, mouse monoclonal), phospho-PERK (125 kDa, 1:500, rabbit
polyclonal), phospho-/total ERK1/2 (42, 44 kDa, 1:1000, mouse monoclonal), phospho/total-Akt (60 kDa, 1:1000, rabbit polyclonal), phospho-MEK and all of the secondary
antibodies (anti-rabbit-HRP, anti-mouse-HRP, and anti-goat-HRP) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA).

Anti-Atg5 (49 kDa, 1:1000, rabbit

polyclonal) was purchased from Abcam (Cambridge, MA).

Anti-LC3 (17/19 kDa,

LC3II/LC3I, rabbit polyclonal) was obtained from Novus Biologicals (Littleton, CO).
Commercially available siRNA duplexes to knockdown RNA/protein levels were
from Qiagen (Valencia, Ca): CD95 (SI02654463; SI03118255); ATG5 (SI02655310);
Beclin 1 (SI00055573, SI00055587). The plasmids to express green fluorescent protein
(GFP)- tagged human LC3; wild type and dominant negative PERK (Myc-tagged
PERKΔC); were kindly provided by Dr. S. Spiegel, VCU, Dr. J.A. Diehl University of
Pennsylvania, Philadelphia, PA.
3.2 Cell Culture
HCT116 (p53 wild type) cells are a colon cancer cell line from American Type
Culture Collection (ATCC). These cells express an active K-RAS D13 mutation. HCT116
stably transfected cell lines were previously generated. The empty vector HCT116 cell
line is genetically deleted for K-RAS D13. These cells were then transfected to express a
mutant active H-Ras (H-Ras V12) where the plasmid was kindly provided by Dr. M.
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Wigler (Cold Spring Harbor, NY). HCT116 H-RAS V12 cells were then transfected with
either an active mutant of PI3K, Ral, or Raf. These cells were maintained in Geneticin
(GIBCOBRL Life Technologies, Grand Island, NY) for selection. All the above cells were
cultured in DMEM medium with L-glutamine and supplemented with 5% (v/v) fetal
bovine serum and 2% (v/v) penicillin/streptomycin according to supplier instructions.
HD6 cells (p53 mutant) were subcloned from HT29 cells and recloned as HD6-4 cell line.
The cells are from the lab of Eileen Friedman
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. The HD6-4 cell line has wildtype ras

genes. These cells were transfected with either overexpression of K-Ras (G3), an active KRas mutant (V1), or an active H-Ras mutant (H18). Both active mutants are mutated at
codon 12 from Gly to Val. These transfectants as well as the parental HD6-4 cell line were
maintained in DMEM medium with L-glutamine and supplemented with 10% (v/v) fetal
bovine serum and 2% (v/v) penicillin/streptomycin according to supplier instructions.
SW480 cells are from ATCC. These cells were maintained in RPMI medium with Lglutamine and supplemented with 10% (v/v) fetal bovine serum and 2% (v/v)
penicillin/streptomycin according to supplier instructions. SW620 cells (ATCC), patient
matched to SW480 cells were maintained in DMEM with L-glutamine and supplemented
with 10% (v/v) fetal bovine serum and 2% (v/v) penicillin/streptomycin according to
supplier instructions. SW620 cells expressing LASS6 were provided by Dr. VoelkelJohnson. All cells were routinely subcultured and maintained in a 10 % CO2/90 %
air/37oC humidified incubator. In addition, all cells were examined frequently for
contamination with bacteria or fungus by visual inspection. Also, cells were routinely
tested for mycoplasma contamination. Cells were not cultured in reduced serum media
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during any study in this manuscript. Table 3.1 outlines the various cell lines that were
used.
3.3 Assessment of Cell Viability
A method used for evaluating cell viability involves the trypan blue
inclusion/exclusion of isolated cells under light microscopy and scoring the percentage of
cells exhibiting blue staining indicative of cell death. Cells were washed once with PBS
and trypsinized to detach cells from 12 well plates. Cells were centrifuged for 4 minutes at
1400 rpm at 25ºC (room temperature). The media was then aspirated off and trypan blue
was added to the tube depending on pellet size. The trypan blue inclusion/exclusion
represents the integrity of the cellular membrane in that healthy, viable cells contain intact
cell membranes and thus reject the trypan blue stain, while damaged cells exhibit a blue
color due to a compromised cellular membrane that allows the trypan blue stain to be
incorporated into the cell. Viable cells and trypan blue stained cells were counted in a
hemacytometer viewed under a microscope. Calculations of cell death were made using the
number of trypan blue positive cells divided by alive cell number multiplied by 100 to get
the percentage of cell death.
3.4 Western Blot Analysis for Protein Expression
a.) Protein Isolation
Cells were plated at an appropriate density and treated with drug. At the indicated times
after drug exposure, cells were washed in PBS and then scraped from the using whole-cell
lysis buffer (0.5 M Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) βmercaptoethanol, 0.02% (w/v) bromophenol blue). A 1:20 dilution of protease inhibitor
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cocktail (Roche) and a 1:100 dilution of phosphatase inhibitor cocktail (Roche) was also
added to the lysis buffer. The samples were then vortexed to dislodge the pellet, heated at
95-100ºC for 5 minutes and placed immediately on ice.
b.) Electrophoresis
50-100 µg aliquots of cell protein (depending on the protein analyzed) was loaded onto a
polyacrylamide gel (10-15%, depending on the size of the protein analyzed). Samples
were run in a SDS-PAGE running buffer (3.02g Tris-base, 14.40g glycine, 1.0g SDS, QS
to 1 L deionized water) for approximately 6 hours with a constant current of 60 mA.
Proteins were transferred onto a nitrocellulose membrane electrophoretically for 4 hours on
ice at 450 mA in transfer buffer (5.8g Tris-base, 2.9g glycine, milli-Q water to 800 ml, 1.8
ml 20% (w/v) SDS, 200 ml methanol.)
c.) Immunoblotting
The membrane was blocked in TBS-tween buffer containing 5% (w/v) non-fat dry milk for
30 minutes. After removal of the blocking solution, the primary antibody was added at a
certain dilution to fresh block solution.

After an overnight exposure with the primary

antibody at 4ºC with orbital shaking, the antibody/wash solution was removed and the
membrane was washed with blotto wash (5 x 5 minutes).

The membrane was then

incubated with the corresponding goat anti-mouse or rabbit secondary antibody for 2 hours
at room temperature with orbital shaking. The secondary antibody was then removed and
the membrane washed in blotto wash again, 5 x 5 minutes.

All immunoblots were

visualized by ECL. For presentation, immunoblots were digitally scanned at 600 dpi using
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Adobe PhotoShop CS2, and their color removed and figures generated in Microsoft
PowerPoint.
3.5 Co-Immunoprecipitation: DISC Formation
Cells were plated at an appropriate density and treated with drug. At the indicated
times after drug exposure, cells were washed in PBS and then scraped from the flask in
200 µl NP40 Buffer (50 mM Tris-HCL pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.75%
NP40). The cells are then harvested and placed in a 1.5 ml eppendorf tube and pipetted up
and down 10 times using a 25-gauge needle. The cells are placed on iced for 5 minutes
and then spun down at 6000 rpm for 3 minutes. The supernatant is collected and antiCD95 is added to the samples (8 µl/sample). The cells are left at 4ºC overnight rocking.
The next day, 25 µl/sample of protein Sepharose beads are added, shaking or rocking at
4ºC for an hour. The samples are then spun at 8000 rpm for 3 minutes. The supernatant is
collected for immunoblot analysis of the GAPDH for loading control. The pellet is saved,
washed with NP40 buffer, and spun down again two more times at 8000 rpm for 3
minutes. Approximately 60 µl of lysis buffer (0.5 M Tris-HCl, pH 6.8, 2% (w/v) SDS,
10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol, 0.02% (w/v) bromophenol blue) is added
per sample, placed on ice for 10 minutes, and boiled for 5 minutes. The samples are stored
at 80º C until immnoblot analysis.
3.6 Colony Formation Assay for Cell Survival
Cells were plated as single cells (100– 125 cells/well) in a 6 well plate. Twenty
four hours after plating, cells were treated with three different drug concentrations of each
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drug as well as the combination of both drugs for 48 h. After 48 h, the drug-containing
media was carefully removed, the cells were washed once, and fresh media lacking drugs
were added. Colony formation assays were cultured for an additional 10 to 14 days. Upon
colony formation, the medium was removed and the cells washed in 1X PBS. The cells
were then fixed on the dish by adding 100% methanol for 10 minutes. The methanol was
then removed and the cells were placed in a 0.1% (v/v) crystal violet (Sigma-Aldrich)
staining solution for 1 h. Colonies containing more than 50 cells were then counted and
normalized to the control cell survival sample.

The survival data shown includes

individual assays performed at multiple dilutions with a total of six plates per data point,
repeated for a total of three experiments.
3.7 Flow Cytometric Assay
Cells were plated in 12-well plates at a concentration of approximately 5 x 104 cells
per well and 24 h later treated with drug. The medium was removed 48 h after treatment,
from the cells and placed in 15 ml conical tubes (Fisher Scientific, Pittsburgh, PA). The
cells were then washed in 1X PBS, trypsinized, and harvested with appropriate medium
and also placed in the 15 ml conical tubes. The samples were then centrifuged at 1400
RPM for 5 minutes at 25º C in an Eppendorf 5804 R centrifuge. The supernatant was then
aspirated and the cells re-suspended in ice cold PBS. The samples were centrifuged again
at the same specifications. The supernatant was again aspirated. A 1:10 dilution of
Annexin buffer (Annexin V-FITC kit, PD PharMingen). was prepared and 100 µl of this
diluted buffer was added to each tube. Next, 1 µl of Annexin V/FITC solution and 5 µl of
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dissolved propidium iodide were added to the cell suspensions. Tubes were kept on ice in
the dark for fifteen minutes. After this time period, 400 µl of ice-cold 1X binding buffer
was added to the suspensions and mixed gently. Flow cytometry was performed using a
Becton Dickinson FACScan flow cytometer (Mansfield, MA).
3.8 Recombinant Adenoviral Vectors: Infection in Vitro
We purchased recombinant adenoviruses to express (CRM-A, c-FLIPs, Bcl-xL,
XIAP) or to express dominant negative (Akt, MEK, caspase 9, or activated MEK1 or
caAkt) as well as a negative control using CMV (Vector Biolabs, Philadelphia, PA).
rAAV vectors mediate long-term gene transfer without any known toxicity and can be used
to transfer exogenous genes. In vitro adenoviral infections were performed 24 hours after
plating cells. Monolayer cultures were washed in PBS prior to infection and specific virus
was added to the monolayer cultures in serum-free growth medium at an m.o.i.
(multiplicity of infection) of 25 (m.o.i. = # of virus per cell).

The dishes were then placed

on a rocker for 4 hours in a humidified atmosphere of 5% (v/v) CO2 at 37º C. The serum
free growth medium was removed after 4 hours and the appropriate medium was added
back to the cells and allowed to incubate overnight in the same humidified atmosphere.
The expression of the recombinant viral transgene was allowed to occur for 24 h to ensure
adequate expression of transduced gene products before drug exposures.
3.9 Transfection using Small Interfering RNA Molecules (siRNA) or plasmids
RNA interference or gene silencing for down-regulating the expression of specific
siRNA was performed using validated target sequences designed by Ambion (Austin, TX).
Plasmids were used at a concentration of 1 µg/µl or appropriate vector control plasmid
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DNA. For siRNA, 10 nM concentration of the annealed siRNA or the negative control (a
"scrambled" sequence with no significant homology to any known gene sequences from
mouse, rat, or human cell lines) were used. The siRNA molecules were transfected into
cells according to the manufacturer's instructions.
Briefly, cells were plated and allowed to sit overnight until about 80% confluent.
For each well 2 µl of siRNA (or 1µl/µg plasmid) was diluted in 100 µl pen-strep-and-FBSfree medium (100 µl for chamber slides), in a 96 well plate. For each well, 2 µl of
lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) was diluted into 100 µl pen-strepand-FBS-free medium in a separate tube. The two solutions were incubated separately for
approximately 5 minutes, then combined and incubated at room temperature for 30
minutes. After incubation, the total mix (400 µl) was added to each well. Cells were
incubated for 4 hours at 37º C with gentle rocking. After 4 hours, the media was then
replaced with 1 ml of its regular media with antibiotics and FBS.
3.10 Immunohistochemistry: CD95 surface localization
Cells were plated on chamber slides, collected from the culture the next day, and
washed once with DPBS (Dulbecco’s PBS without calcium and magnesium, Mediatech,
Inc, Herndon, VA). The cells were then fixed in a solution of 4% paraformaldehyde in PBS
for twenty minutes. Cells were washed again in DPBS and nonspecific binding was
blocked with a 1% (v/v) BSA and 2% (v/v) rat serum DPBS solution for 1 hour. Slides
were then incubated with a 1:100 dilution of the primary anti-Fas in block solution
overnight in a humidified chamber. The next day, slides were washed once in DPBS and
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incubated for 1 hour with secondary goat anti-mouse Alexa 488/647 at a dilution of 1:500
in block solution. Slides were washed after an hour, and coverglasses were mounted onto
the glass slides using Vectashield with Dapi (Calbiochem, Madrid, Spain). Preparations
were observed in a Zeiss LCM 510 meta-confocal microscope and analyzed using the Axio
2.0 software. No labeling was observed when using the secondary antibodies alone.
3.11 GFP-LC3 Assay
The green fluorescent protein (GFP)-tagged microtubule-associated protein 1 light
chain 3 (LC3) expression vector was kindly provided by Dr. S. Spiegel, (VCU) and Dr.
J.A. Diehl, (University of Pennsylvania, Philadelphia, PA). LC3 is recruited to the
autophagosomal membrane during autophagy. Therefore, GFP-tagged LC3-expressing
cells have been used to demonstrate the induction of autophagy. GFP-LC3 cells present a
diffuse distribution under control conditions, whereas a punctate pattern of GFP-LC3
expression) is induced by autophagy. Cells were transiently transfected with the GFP-LC3
vector using lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA). After
overnight culture, cells were treated with the appropriate drug or drugs for 6 hours and 24
hours and examined under a fluorescence microscope. To quantify autophagic cells after
drug treatment, the number of GFP-LC3 vacuoles among 50X GFP-positive cells were
counted.
3.12 Statistical Analyses
The effects of various treatments were analyzed using one-way ANOVA and a twotailed t test. Differences containing a p-value less than 0.05 were considered statistically
significant. The experiments shown are the means of multiple individual points (+/-SEM).
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Cell Line

Media

Antibiotic in
Culture

Transfection

p53
status

Other
Mutations

HCT116 wt

5%
DMEM

\

\

Wt

K-RAS

HCT116 V12

5%
DMEM

Geneticin
(0.05mg/ml)

\

Wt

Harvey-RAS
V12 mutation

HCT116 V12 vector

5%
DMEM

Geneticin
(0.05mg/ml)

empty vector,
K-RAS
deleted

Wt

HCT116 V12 -40

5%
DMEM

Geneticin
(0.05mg/ml)

PI3K

Wt

HCT116 V12- 37

5%
DMEM

Geneticin
(0.05mg/ml)

RAL

Wt

HCT116 V12- 35

5%
DMEM

Geneticin
(0.05mg/ml)

Raf

Wt

DLD1

5%
DMEM

\

\

Mutant

SW480

10%
RPMI

\

\

Mutant

HT29

10%
DMEM

\

\

Mutant

HD6-4

10%
DMEM

Geneticin
(0.05mg/ml)

Empty Vector

mutant
(inactive)

HD6-4 G3

10%
DMEM

Geneticin
(0.05mg/ml)

overexpress
wt K-RAS

mutant
(inactive)

HD6-4 V1

10%
DMEM

Geneticin
(0.05mg/ml)

K-RASG12V
(active)

mutant
(inactive)

HD6-4 H18

10%
DMEM

Geneticin
(0.05mg/ml)

H-RASG12V
(active)

mutant
(inactive)

wt RAS (no
mutant RAS)

Table 3.1. Cell Line Information. This table consists of cell lines used during the
sorafenib and vorinostat project.

CHAPTER 4 RESULTS: Sorafenib and Vorinostat
4.1 Sorafenib and Vorinostat decrease cell viability in colon cancer cells
Colon cancer cells were plated at a density of 1.2 x104 cells per well in a 12 well
plate. Cells were treated with vehicle (DMSO), 6 µM sorafenib (3 µM sorafenib for
HCT116 wt cells), 500 nM vorinostat, or the combination of both drugs. After 96 hours,
trypan blue exclusion assays were performed as described in materials and methods.
Treatment of HCT116 wt, DLD1, SW480, and SW620 cells resulted in a greater than
additive induction of cell killing than either individual agent alone.

However, the

percentage of cell death was much lower in SW620 cells than compared to any other cell
line (Figure 4.1).
4.2 Sorafenib and Vorinostat synergize to kill HCT116 wt cells in colony formation
assays
We next used colony formation assays to determine long term effects on cell
survival. Colon cancer cells were plated as single cells (100-125 cells/well) in a 6 well
plate. There was one treatment condition per plate. Twenty four hours after plating, cells
were treated with either Sorafenib (3, 4.5 or 6 µM) or Vorinostat (0.25, 0.375, or 0.5 µM),
and the combination of both drugs as indicated at a fixed concentration ratio to perform
median dose effect analysis for the determination of synergy. Forty eight hours after drug
exposure, the media was changed and the cells were cultured in drug free media for an
additional 10-14 days. Cells were fixed, stained with crystal violet, and colonies >50
cells/colony counted as described in materials and methods under colony formation assay.
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Colony formation data was entered into the Calcusyn program and combination index (CI)
values determined. CI values less than 1 indicates synergy, equal to 1 indicates additive
interactions, and CI values > 1 indicates antagonism (Figure 4.2). Similar results are
obtained with SW480 (Figure 4.3) but not with DLD1 colon cancer cells (Figure 4.4).
4.3 Sorafenib and sodium valproate synergize in colony formation assays to kill colon
cancer cells
We used an unrelated clinically used HDACI, sodium valproate instead of
vorinostat to determine if similar results could be obtained. Colon cancer cells were plated
as single cells (100-125 cells/well) in a 6 well plate. There was one treatment condition
per plate. Twenty four hours after plating, cells were treated with either Sorafenib (3, 4.5,
or 6 µM) or sodium valproate (Val. 0.5, 0.75, 1.0, 1.25, or 1.5 mM), and the combination
of both drugs as indicated at a fixed concentration ratio to perform median dose effect
analysis for the determination of synergy. Forty eight hours after drug exposure, the media
was changed and the cells were cultured in drug free media for an additional 10-14 days.
Cells were fixed, stained with crystal violet, and colonies >50 cells/colony counted as
described in materials and methods under colony formation assay. Colony formation data
was entered into the Calcusyn program and combination index (CI) values determined. CI
values less than 1 indicates synergy, equal to 1 indicates additive interactions, and CI
values > 1 indicates antagonism (Figure 4.5). Similar results are obtained with SW480
(Figure 4.6).
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4.4 Sorafenib and Vorinostat induce Apoptosis by Flow Cytometry
We used flow cytometry as a better measure to detect apoptosis than trypan blue
exclusion assays. The trypan blue exclusion assay measures late apoptotic events, while
flow cytometry can detect early and late apoptotic events. HCT116 wt cells were plated at
a density of 2.5x104 cells per well in a 12 well plate. Cells were treated vehicle (DMSO),
3 µM sorafenib, 500 nM vorinostat, or the combination of both drugs. After 48 hours,
flow cytometry was performed using Annexin V/propidium iodide staining as described in
materials and methods. Treatment of the HCT116 wt cells resulted in a greater than
additive induction of cell killing than either individual agent alone (Figure 4.7A). Similar
results are shown in the SW480 cell line (Figure 4.7B). Based upon these interesting
findings, the mechanism of this drug combination was investigated.
4.5 Basal activation of ERK1/2 predicts for a Sorafenib and Vorinostat response
Ras effector mutants were used to decipher the mechanism of action of the
combination of sorafenib and vorinostat. Many colon cancer patients have RAS mutations,
and exploring the sensitivity of this drug combination on active mutants of the MAP kinase
pathways would further aid in the mechanism of action. HCT116 wt, HCT116 V12, as
well as the HCT116 V12 transfectants were plated at a density of 2.5x104 cells per well in
a 12 well plate. Cells were treated vehicle (DMSO), 3 µM sorafenib, 500 nM vorinostat,
or the combination of both drugs. After 48 hours, flow cytometry was performed using
Annexin V/propidium iodide staining as described in materials and methods. HCT116 cells
genetically deleted for expression of mutant K-RAS D13 (vector) are less sensitive to
treatment by sorafenib and vorinostat, than in the parental wild type cells. Lethality was
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restored in cells transfected to express H-RAS V12 or H-RAS V12 RAF, but not in cells
expressing H-RAS V12 RAL or H-RAS V12 PI3K (Figure 4.8). This indicates that
activation of the Raf/MEK/ERK MAP kinase pathway predicts for drug toxicities, and that
Ras mutations can be used as a predictor tool for the sensitivity to this combination drug
treatment. This also indicates that activation of ERK1/2 in the absence of PI3K or RAL
GDS activation promotes HDACI toxicity.
HT29 colon cancer cells express a mutated active B-Raf protein, but do not express
mutated K-RAS. In a similar manner to HCT116 cells, expression of mutated active KRAS protein in HT29 (HD6-4) cells enhanced the lethality of the drug combination (Figure
4.9). However the toxic effect was not as profound as that observed in other colon cancer
cell types.
4.6 Sorafenib and Vorinostat decrease activation of ERK1/2 but not Akt in HCT116
wt cells
We explored the MAP kinase pathways further by reviewing the expression of
other members of the RAF/MEK/ERK MAP kinase pathway such as the phosphorylation
of ERK and reviewing the PI3K pathway and the role of AKT. HCT116 cells were plated
at a density of 1 x106 cells per 10 cm dish. Cells were exposed to vehicle (DMSO) or the
combination of sorafenib and vorinostat. Cells were isolated 24 to 96 hours after drug
exposure and subjected to SDS-PAGE and immunoblotting as described in materials and
methods.

The phoshorylation of ERK1/2, and Akt was determined (Figure 4.10).

Phosphorylation of Akt (S473) was not altered over the course of 96 hours in HCT116wt
cells. In a similar manner to findings in hepatoma cells, sorafenib and vorinostat exposure
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transiently inactivated ERK1/2 by 48 hours in combined drug-exposed cells. This is
another indication that the PI3K pathway is not involved in the mechanmism of action of
this combination treatment.
4.7 Activated MEK1 suppresses the toxicity of Sorafenib and Vorinostat
Based on the findings in Figure 4.10, we determined whether expression of
constitutively activated MEK1 and/or Akt protected cells from vorinostat and sorafenib
exposure. HCT116 wt cells were plated at a density of 2.5x104 cells per well in a 12 well
plate. Cells were infected 24 hours after plating with empty vector control virus (CMV) or
viruses to express constitutively active MEKEE (ca-MEKEE), constitutively active Akt
(caAKT1), or the combination of the active Akt and active MEKEE viruses as described in
materials and methods. The next day, cells were treated vehicle (DMSO), 3 µM sorafenib,
500 nM vorinostat, or the combination of both drugs. After 48 hours, flow cytometry was
performed using Annexin V/propidium iodide staining as described in materials and
methods. Activated MEK1 protected the cells from the increase in cell death seen in the
CMV control. However, active Akt did not cause as significant a decrease in cell death
(agreeing with our data in figure 4.10), indicating that one mechanism of drug toxicity is
via inhibiting the Raf/MEK/ERK MAP kinase pathway and not the PI3K pathway. The
combination of active MEK1 and active Akt did not suppress cell death to a greater extent
than active MEK1 alone (Figure 4.11).

Expression of activated MEK1 maintained

ERK1/2 phosphorylation and active Akt expressed Akt phosphorylation in non-treated
cells (Figure 4.11, inset).
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4.8 DNMEK1 increased sorafenib and vorinostat toxicity in HCT116 wt cells
In view of the observation that activated MEK protected cells from sorafenib and
vorinostat toxicity, studies were performed to determine the effects silencing MEK and/or
AKT. HCT116 wt cells were plated at a density of 2.5x104 cells per well in a 12 well
plate. Cells were infected 24 hours after plating with empty vector control virus (CMV) or
viruses to knockdown MEKEE (DNMEK1), Akt (DNAKT1), or the combination of the
DNAKT and active DNMEK1 viruses as described in materials and methods. The next
day, cells were treated vehicle (DMSO), 3 µM sorafenib, 500 nM vorinostat, or the
combination of both drugs. After 48 hours, flow cytometry was performed using Annexin
V/propidium iodide staining as described in materials and methods.

Expression of

dominant negative MEK1, but not dominant negative Akt, enhanced the toxicity of
sorafenib, vorinostat, and the drug combination (Figure 4.12). The effects we saw with
DNAKT could be due to an increase in JNK activity which would promote a protective
form of autophagy in these cells.
4.9 Sorafenib and Vorinostat increase the phosphorylation of p38 and JNK in
HCT116 wt cells
We next explored the JNK and p38 MAP kinase pathways to understand their
involvement in sorafenib and vorinostat lethality. HCT116 cells were plated at a density of
1 x106 cells per 10 cm dish. Cells were exposed to vehicle (DMSO), 3 µM sorafenib, 500
nM vorinostat, or the combination of both drugs. Cells were isolated 6 and 24 hours after
drug exposure and subjected to SDS-PAGE and immunoblotting as described in materials
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and methods. The phoshorylation of p38 and JNK was determined. Phospho-p38 and
phospho-JNK expression levels transiently increased after 6 hours with the drug
combination (Figure 4.13). This is different from data seen in hepatoma cells (where no
activation was observed).

Consequently, JNK activation could again lead to a protective

form of autophagy.
4.10 DNp38 or JNK IP did not suppress sorafenib and vorinostat lethality in HCT116
wt cells
Based on the fact that p38 and JNK was transiently activated, we used molecular
approaches to define the role of the p38 and JNK pathways. HCT116 wt cells were plated
at a density of 2.5x104 cells per well in a 12 well plate. Cells were infected 24 hours after
plating with empty vector control virus (CMV) or virus to knockdown p38 (DNp38).
Thirty minutes prior to drug exposure cells were treated as indicated with vehicle (DMSO)
or the JNK inhibitory peptide (JNK-IP, 10 μM). The next day, cells were treated vehicle
(DMSO), 3 µM sorafenib, 500 nM vorinostat, or the combination of both drugs. After 48
hours, flow cytometry was performed using Annexin V/propidium iodide staining as
described in materials and methods.

Expression of dominant negative p38 MAPK

modestly suppressed vorinostat lethality but did not alter the lethality of sorafenib and
vorinostat exposure. Inhibition of JNK1/2 using the cell permeant JNK inhibitory peptide
blunted sorafenib toxicity and enhanced the lethality of sorafenib and vorinostat exposure
(Figure 4.14).
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4.11 Overexpression of c-FLIP or ectopic expression of CrmA did not reduce
sorafenib and vorinostat lethality in HCT116 wt cells, but c-FLIP did significantly
reduce lethality in SW480 cells
Previous studies in our laboratory have shown that the downregulation of antiapoptotic proteins or the overexpression of pro-apoptotic proteins mediate the toxic effects
of sorafenib and vorinostat combination drug therapy. We explored the extrinsic apoptotic
pathway first and investigated the role of caspase 8, by using inhibitors. Cells were plated
at a density of 2.5 x 104 in 12 well plates. Cells were allowed to attach overnight and the
next day cells were infected with adenovirus FLIP, cytokine response modifier A (CrmA),
as well a CMV control adenovirus. FLIP is a caspase 8 inhibitor. CrmA is cowpox virusencoded anti-apoptotic protein that is a member of the serpin family which specifically
inactivates the cellular proteins caspase 1, caspase 8 and granzyme B
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. Cells were

infected as described in materials and methods. The next day, cells were treated with
vehicle (DMSO), 3 µM sorafenib (6 µM in SW480 cells), 500 nM vorinostat, or the
combination of both drugs. After 48 hours, flow cytometry was performed using Annexin
V/propidium iodide staining as described in materials and methods. Overexpression of
FLIP-s weakly blunted drug –induced cell killing HCT116 wt cells (Figure 4.15). CrmA
alone had toxic effects in vehicle DMSO treated HCT116 wt cells and the addition of the
individual drugs or the combination did not suppress cell death. FLIP-s, however, did
reduce the toxic effects of sorafenib and vorinostat in SW480 cells, similar to previous
studies in our laboratory (Figure 4.16). Total cell lysates were analyzed by immunoblotting
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with anti-FLIP to assess the levels of expression of infected FLIP in both cell lines (Figure
4.15 and 4.16, inset).
4.12 Overexpression of XIAP did not reduce sorafenib and vorinostat lethality in
HCT116 wt cells, but overexpresion of Bcl-xL or DNCaspase 9 did reduce the toxic
effects of combination treatment
We directed our attention to the intrinsic apoptotic pathway to urther investigate its
role in sorafenib and vorinostat combination treatment. HCT116 wt cells were plated at a
density of 2.5 x 104 in 12 well plates. Cells were allowed to attach overnight and the next
day cells were infected with adenovirus XIAP, dominant negative caspase 9 (DNcaspase
9), Bcl-xL, as well a CMV control adenovirus.

Cells were infected as described in

materials and methods. The next day, cells were treated with vehicle (DMSO), 3 µM
sorafenib, 500 nM vorinostat, or the combination of both drugs. After 48 hours, flow
cytometry was performed using Annexin V/propidium iodide staining as described in
materials and methods. XIAP, a member of inhibitor of apoptosis (IAP) proteins, did not
reduce drug lethality in HCT116 wt cells. Overexpression of Bcl-xL or expression of
dominant negative caspase 9 suppressed sorafenib+vorinostat toxicity in HCT116 cells,
arguing that the drugs were using the intrinsic pathway to kill this tumor cell type (Figure
4.17).
4.13 Antiapoptotic and Proapoptotic protein expression during Sorafenib and
Vorinostat combination response
To delineate the role of specific pro-apoptotic and anti-apoptotic proteins,
immunoblot analysis in vorinostat and sorafenib treated HCT116 wt cells were performed.
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Cells were plated at 1.5 x 106 in 10 cm dishes. Twenty four hours after plating, cells were
treated with vehicle (DMSO), 3 µM sorafenib, 500 nM vorinostat, or the combination of
both drugs. Six and twenty four hours later, cells were isolated and western blot analysis
was performed as described in materials and methods. The antiapoptotic BCL-2 family
members, Bcl-2 and Bcl-xL, remained constant over a time period of 24 hours.

FLIP-s

also remained constant, which is very different from other cancer cell lines we have tested.
Uncleaved bid even remained constant over the 24 hour period. There was modest
reduction of Mcl-1 expression at 6 hours in combined treatment, however. Twenty four
hours after drug exposure, the expression of procaspase-3 had declined (indicating caspase
3 cleavage) after combined, but not individual drug exposure (Figure 4.18). This indicates
that the apoptotic pathway is involved.
4.14 Bcl-2 / Bcl-xL / Mcl-1 inhibitor GX15-070 (Obatoclax) increases cell death in
Colon Cancer Cells
As an aside, we determined whether inhibition of protective BCL-2 family
members facilitated drug-induced cell killing. Colon cancer cells were plated at a density
of 1.2 x104 cells per well in a 12 well plate. Twenty four hours after plating, cells were
treated with vehicle (DMSO), 3 µM sorafenib (6 µM in SW480s), 1 mM sodium valproate
or the combination of both drugs with or without 100 nM obatoclax. Obatoclax is a pan
inhibitor of the antiapoptotic members, Bcl-2, Bcl-xL, and Mcl-1. Twenty four or forty
eight hours later, the trypan blue exclusion assay was performed as described in materials
and methods. Treatment of cells with pharmacologically achievable concentrations of
Obatoclax significantly increased HCT116 or SW480 cell mortality (Figures 4.19 and
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4.20). Obatoclax did not significantly enhance the toxicity of sorafenib but in HCT116
cells this drug did promote the lethality of sodium valproate, as well as enhancing the
toxicity of sorafenib and valproate exposure.

This indicates that cell death can be

facilitated thorugh targeting mitochondrial protective proteins.
4.15 HCT116 wt cells mount a death response to Sorafenib and Vorinostat that is Fasindependent; however, SW480 cells have a Fas-dependent mechanism
Prior studies have demonstrated in hepatoma cells that sorafenib and vorinostat
toxicity was dependent on activation of CD95 107, 108. Since we have demonstrated that the
apoptotic pathway is involved with our drug combination in colon cancer cells, we decided
to test the role of CD95 in HCT116 and SW480 cells. Cells were plated at a density of 2.5
x 104 in 12 well plates. Cells were allowed to attach overnight and the next day cells were
transfected with siScramble, or knockdown of CD95 (siCD95), a death receptor and part of
the extrinsic apoptotic pathway. Cells were transfected as described in materials and
method. The next day, cells were treated with vehicle (DMSO), 3 µM sorafenib (6 µM for
SW480), 500 nM vorinostat, or the combination of both drugs. After 48 hours, flow
cytometry was performed using Annexin V/propidium iodide staining as described in
materials and methods.

Interestingly, knockdown of CD95 increased cell death in

HCT116 wt cells. In SW480 cells, knockdown of CD95 decreased cell death compared to
Si-scramble group (Figure 4.21). Collectively, this data demonstrates that after sorafenib
and vorinostat exposure SW480 cells respond in a manner similar to that observed in many
other tumor cell types with CD95 / extrinsic pathway activation, but that HCT116 cells
display an unexpected phenomenon wherein CD95 signaling is cyto-protective.
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4.16 Knockdown of CD95 in SW480 cells did not prevent cell killing by GX15-070
(Obatoclax)
We have shown that knockdown of CD95 protects SW480 cells from sorafenib and
vorinostat induced cell death. Thus, we explored whether knockdown of CD95 and the
addition of a third drug, obatoclax (where we have seen a significant amount of cell death)
would continue to protect cells from drug-induced cell death. SW480 cells were plated at a
density of 2.5 x 104 in 12 well plates. Cells were allowed to attach overnight and the next
day cells were transfected with siScramble, or knockdown of CD95 (siCD95). Cells were
transfected as described in materials and method. Twenty four hours after transfection,
cells were treated with vehicle (DMSO) or Obatoclax (100 nM) followed by, vehicle
(DMSO), sorafenib (6 µM), sodium valproate (1.0 mM) or sorafenib+valproate. Forty
eight hours after exposure, cells were isolated and viability determined via trypan blue
exclusion assay (± SEM, n = 3 independent studies). Although knockdown of CD95
suppressed sorafenib+valproate induced cell death, the addition of obatoclax ameliorated
this inhibition (Figure 4.22).
4.17 Lack of Fas/CD95 surface expression in HCT116 wt cells and SW620 cells, but
not in SW480 cells
We next explored CD95 surface expression, since we have already established that
CD95 protects SW480 cells from sorafenib and vorinostat cell death and does not protects
HCT116 wt cells. Colon cancer cells were plated in 4 well chamber slides at a density of
15,000 cells per well.

Next day, cells were treated with vehicle (DMSO) or the

combination of sorafenib and vorinostat for 3, 6, and 8 hours. Immunohistochemistry was
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performed as described in materials and methods. HCT116 wt cells did not increase CD95
plasma membrane levels after treatment with sorafenib and vorinostat (Figure 4.23A),
despite the lethal effects with these drugs (Figure 4.23B). Sorafenib and vorinostat toxicity
did correlate with CD95 plasma membrane activation in the SW480 cells (Figure 4.23A).
SW620 cells, patient matched to SW480 cells, showed significantly lower toxicity with the
drug combination (Figure 4.23B) that also correlated with a lack of CD95 activation on the
cell surface (Figure 4.23A) and lower expression of ceramide synthase (LASS6).
4.18 DISC formation in HCT116 wt cells and SW480 cells
We further explored the extrinsic pathway by determining if there was DISC
formation in the HCT116 wt and SW480 cells. DISC is crucial to CD95 receptor mediated
apoptosis. Cells were plated at a density of 2.0 x 106 cells per 100 cm dish. The next day
cells were treated with the combination of 3 µM sorafenib (6 µM in SW480s) and 500 nM
vorinostat or vehicle (DMSO). Combined treatment in HCT116 wt cells with vorinostat
and sorafenib promoted only a weak association of pro-caspase 8 with CD95. Grp78
(Bip), a protein involved in ER stress, strongly associated with CD95 (Figure 4.24A). In
SW480 cells, combination treatment promoted the rapid association of procaspase-8 with
CD95 (Figure 4.24B). This data correlates with other cancer cell lines that have been
tested. Bip also associates with CD95 in SW480 cells (Figure 4.24B).
4.19 Sorafenib and Vorinostat stimulate autophagy in HCT116 cells
In our prior studies combining sorafenib and vorinostat in NSCLC, renal, liver,
melanoma and pancreatic cancer cells induced autophagy. We decided to investigate what
role autophagy played in sorafenib and vorinostat treatment in colon cancer cells. HCT116

73
wt cells were plated in 4 well chamber slides at a density of 15,000 cells per well. The
next day, cells were transiently transfected with GFP-LC3, GFP-LC3 and siRNA beclin1,
or GFP-LC3 and siRNA to Atg5 as described in materials and methods.

The next day,

cells were treated with vehicle (DMSO), 3 µM sorafenib, 500 nM vorinostat, or the
combination of both drugs. Six hours after drug exposure cells were visualized at 40X
using an Axiovert 200 fluorescent microscope under fluorescent light using the FITC filter.
The mean number of autophagic vesicles per cell from random fields of 40 cells were
counted (± SEM, n = 3). Sorafenib and vorinostat induced autophagy in the HCT116 wt
cells as indicated by GFP-LC3 vesicularization and this was suppressed by knockdown of
beclin-1 (Figure 4.25A and Figure 4.25B).
4.20 Knockdown of Beclin 1 expression enhanced Sorafenib and Vorinsotat toxicity
We have already shown (Figure 4.25) that knockdown of beclin 1 suppressed
sorafenib and vorinostat autophagy. We next investigated the effect of knockdown beclin
1 on cell death in HCT116 cells. Cells were plated at a density of 2.5 x 104 in 12 well
plates. Cells were allowed to attach overnight and the next day cells were transfected with
siScramble or knockdown of beclin 1 (si-beclin1). Cells were transfected as described in
materials and method. The next day, cells were treated with vehicle (DMSO), 3 µM
sorafenib, 500 nM vorinostat, or the combination of both drugs. After 48 hours, flow
cytometry was performed using Annexin V/propidium iodide staining as described in
materials and methods. Knockdown of beclin 1 enhanced drug toxicity (Figure 4.26).
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4.21 Sorafenib and Vorinostat induce autophagy that is CD95 dependent in HCT116
cells
Since CD95 is likely to be cytoprotective in HCT116 wt cells, we explored the
effects of CD95 knockdown on autophagy. Cells were plated in 4 well chamber slides at a
density of 15,000 cells per well. The next day, cells were transiently transfected with
GFP-LC3 and siscramble or GFP-LC3 and siRNA CD95, as described in materials and
methods. The next day, cells were treated with vehicle (DMSO), 3 µM sorafenib, 500 nM
vorinostat, or the combination of both drugs. Six hours after drug exposure cells were
visualized at 40X using an Axiovert 200 fluorescent microscope under fluorescent light
using the FITC filter. The mean number of autophagic vesicles per cell from random fields
of 40 cells were counted (± SEM, n = 3). Knockdown of CD95 suppressed drug treatment
GFP-LC3 vesicularization (Figure 4.27A and 4.27B). Collectively, this data and the data in
Figure 4.21 demonstrate that sorafenib and vorinostat treatment promote a form of CD95
activation in HCT116 cells that is non-productive with respect to pro-apoptotic signaling
but is competent to stimulate an autophagic response that is cyto-protective.
4.22 Sorafenib and Vorinostat activated PERK but did not alter eif2a
phosphorylation in HCT116 cells
We next investigated the mechanistic links between sorafenib and vorinostat
lethality and ER stress signaling. We have already shown in HCT116 wt cells the strong
association with CD95 and Bip in DISC formation. Cells were plated at 1.5 x 106 in 10 cm
dishes. Twenty four hours after plating, cells were treated with vehicle (DMSO), 3 µM
sorafenib, 500 nM vorinostat, or the combination of both drugs. Six and twenty four hours
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later, cells were isolated and western blot analysis was performed as described in materials
and methods. We examined the expression of phosphorylated PERK and phosphorylated
eif2α.

The phosphorylation of PERK increased within 6 hours after combination

treatment, yet there was not an apparent increase in the phosphorylation of eif2α (Figure
4.28).
4.23 DnPERK suppresses Sorafenib and Vorinostat–stimulated autophagy in
HCT116 wt cells
In hepatoma cells we have noted that sorafenib and vorinostat exposure promoted a
protective form of autophagy in a CD95- and PERK-dependent fashion. We investigated
the effects of dnPERK on autophagy. HCT116 wt cells were plated in 4 well chamber
slides at a density of 15,000 cells per well. The next day, cells were transiently transfected
with GFP-LC3 and pcDNA or GFP-LC3 and dnPERK, as described in materials and
methods. The next day, cells were treated with vehicle (DMSO), 3 µM sorafenib, 500 nM
vorinostat, or the combination of both drugs. Six hours after drug exposure cells were
visualized at 40X using an Axiovert 200 fluorescent microscope under fluorescent light
using the FITC filter. The mean number of autophagic vesicles per cell from random fields
of 40 cells were counted (± SEM, n = 3). Inhibition of PERK suppressed drug treatment
GFP-LC3 vesicularization (Figure 4.29). {Inset Panel: cells transfected with vector control
plasmid (CMV) or a plasmid to express dominant negative PERK (but not LC3-GFP) were
isolated 6h after drug exposure and lysates subjected to SDS PAGE and immunoblotting to
determine LC3 expression and processing (a representative n = 3)}.
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4.24 Activation of JNK1/2 is dependent on PERK
We next determined whether drug-induced PERK signaling was involved in the
regulation of the JNK1/2 pathway and whether PERK activity was regulated by CD95.
HCT116 cells 24h after plating were transfected with either: a vector control plasmid
(CMV) or a plasmid to express dominant negative PERK; a scrambled siRNA (siSCR) or a
siRNA to knock down CD95 expression (20 nM). Twenty four hours after infection, cells
were treated with vehicle (DMSO) or with sorafenib (3 μM) and vorinostat (500 nM). Six
hours after drug exposure cells were isolated and lysates subjected to SDS PAGE and
immunoblotting to determine the phosphorylation status of PERK and of JNK1/2.
Expression of dominant negative PERK blocked sorafenib and vorinostat –induced PERK
phosphorylation (Figure 4.30A). Expression of dominant negative PERK also abolished
drug-induced JNK1/2 activation (Figure 4.30B). Knock down of CD95 blocked JNK1/2
activation (Figure 4.30D) however, unlike data in hepatoma cells, knockdown of CD95 did
not alter PERK activation (Figure 4.30C). Thus JNK1/2 activation requires separate druginduced signals emanating from both CD95 and PERK.
4.25 Molecular inhibition of JNK1/2 signaling blocked Sorafenib and Vorinostatstimulated autophagy
HCT116 cells 24h after plating in 4 well chamber slides were transfected with a
plasmid to express LC3-GFP. Thirty minutes prior to drug exposure cells were treated as
indicated with vehicle (DMSO) or the JNK inhibitory peptide (JNK-IP, 10 μM). Twenty
four h after infection, cells were treated with vehicle (DMSO), sorafenib (3 μM),
vorinostat (500 nM) or both drugs combined. Six hours after drug exposure cells were
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visualized at 40X using an Axiovert 200 fluorescent microscope under fluorescent light
using the FITC filter. The mean number of autophagic vesicles per cell from random fields
of 40 cells were counted (± SEM, n = 3).

Inhibition of JNK 1/2 blocked drug-induced

vesicularization of GFP-LC3 (Figure 4.31).
4.26 Sorafenib and Vorinostat toxicity is acidic sphingomyelinase dependent
Compared to patient matched SW480 cells, SW620 cells were refractory to druginduced toxicity that correlated with a lack of CD95 activation. Prior studies in hepatoma
cells have demonstrated that inhibition of either the acidic sphingomyelinase (ASMase) or
de novo ceramide synthesis pathways blocked drug-induced CD95 activation and sorafenib
and vorinostat toxicity

107, 108

. It has also been shown that SW620 cells are refractory to

death receptor signaling induced by tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) which has been linked to low expression of ceramide synthase 6 (LASS6)
in the de novo pathway and a lack of ceramide generation after TRAIL exposure

115, 116

.

SW480 cells 24 hours after plating were transfected with siRNA molecules to knock down
expression of acidic sphingomyelinase (ASMase), or transfected with scrambled siRNA
molecules as described in materials and methods. Twenty four h after transfection cells
were treated with vehicle (DMSO) or myriocin (1 μM) and after 30 min, cells then
exposed to vehicle (DMSO), sorafenib (6 μM), vorinostat (500 nM) or both drugs
combined. Forty eight hours after exposure, cells were isolated and stained with trypan
blue dye and cell viability determined by visible light microscopy (± SEM, n = 2). Knock
down of ASMase expression or treatment with the de novo pathway inhibitor myriocin
significantly reduced sorafenib and vorinostat toxicity (Figure 4.32).
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4.27 CD95 activation is acidic sphingomyelinase dependent
SW480 cells 24h after plating in 4 well chamber slides cells were transfected with
siRNA molecules to knock down expression of acidic sphingomyelinase (ASMase), or
LASS6, or transfected with scrambled siRNA molecules as described in materials and
methods. Twenty four h after transfection cells were treated with vehicle (DMSO) or
myriocin (1 μM) and after 30 min, cells then exposed to vehicle (DMSO), sorafenib (6
μM), vorinostat (500 nM) or both drugs combined. Cells were fixed 6h after exposure and
the amount of plasma membrane associated CD95 determined by immunohistochemistry
(± SEM, n = 2). Knockdown of ASMase, myriocin, or LASS6 blocked CD95 activation
(Figure 4.33).
4.28 Overexpression of LASS6 enhanced Sorafenib and Vorinostat-induced CD95
activation and enhanced tumor cell killing in SW620 cells
Based on the data in Figure 4.32 and 4.33, we determined whether expression of
LASS6 in SW620 cells facilitated drug-induced CD95 activation and cell death. SW620
cells were stably transfected with either vector control plasmid or a plasmid to express
LASS6. Twenty four hours after plating, cells were exposed to vehicle (DMSO), sorafenib
(6 μM), vorinostat (500 nM) or both drugs combined. Forty eight hours after exposure,
cells were isolated and stained with trypan blue dye and cell viability determined by visible
light microscopy (± SEM, n = 2). Inset Panel: SW620 cells 24h after plating in 4 well
chamber slides were exposed to vehicle (DMSO), sorafenib (6 μM), vorinostat (500 nM)
or both drugs combined. Cells were fixed 6h after exposure and the amount of plasma
membrane associated CD95 determined by immunohistochemistry (± SEM, n = 2).
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Overexpression of LASS6 in SW620 cells enhanced the toxicity of sorafenib, vorinostat
and the drug combination (Figure 4.34A) which correlated with increased activation of
CD95 (Figure 4.34B). Collectively, this data argues that activation of enzymes within the
de novo ceramide pathway represents a key step in the toxic actions of sorafenib and
vorinostat in colon cancer cells.
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Figure 4.1. Sorafenib and Vorinostat reduce cell viability in colon cancer cells. Colon
cancer cells were treated with 6 µM sorafenib (3 µM for HCT116 wt) and 500 nM
vorinostat continuously for 96 hours. After drug exposure, the trypan blue exclusion assay
was performed. Values represent the means for three separate experiments ± SD. * p <
0.05, greater cell killing than compared with any other treatment condition.
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Figure 4.2. Sorafenib and Vorinostat synergize to kill HCT116 wt cells in colony
formation assays. HCT116 wt cells were treated 12h after plating as single cells (2501500 cells/well) in sextuplicate with vehicle (DMSO), sorafenib (Sor, 3.0-6.0 µM) or
vorinostat (Vor. 250-500 nM), or with both drugs combined, as indicated at a fixed
concentration ratio to perform median dose effect analyses for the determination of
synergy. Combination index (CI) values were determined. CI values less than 1 indicates
synergy, equal to 1 indicates additive interactions, and CI values > 1 indicates antagonism.
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Figure 4.3. Sorafenib and Vorinostat synergize to kill SW480 cells in colony
formation assays. SW480 cells were treated 12h after plating as single cells (250-1500
cells/well) in sextuplicate with vehicle (DMSO), sorafenib (Sor, 3.0-6.0 µM) or vorinostat
(Vor. 250-500 nM), or with both drugs combined, as indicated at a fixed concentration ratio
to perform median dose effect analyses for the determination of synergy. Combination
index (CI) values were determined. CI values less than 1 indicates synergy, equal to 1
indicates additive interactions, and CI values > 1 indicates antagonism.
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Figure 4.4. Sorafenib and Vorinostat does not synergize to kill DLD1 cells in colony
formation assays. DLD1 cells were treated 12h after plating as single cells (250-1500
cells/well) in sextuplicate with vehicle (DMSO), sorafenib (Sor, 3.0-6.0 µM) or vorinostat
(Vor. 250-500 nM), or with both drugs combined, as indicated at a fixed concentration ratio
to perform median dose effect analyses for the determination of synergy. Combination
index (CI) values were determined. CI values less than 1 indicates synergy, equal to 1
indicates additive interactions, and CI values > 1 indicates antagonism.
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Figure 4.5. Sorafenib and sodium valproate synergize in colony formation assays to
kill HCT116 wt cells. HCT116 wt cells were treated 12h after plating as single cells (2501500 cells/well) in sextuplicate with vehicle (VEH, DMSO), sorafenib (Sor., 3.0-9.0 μM)
or sodium valproate (Val. 0.5-1.5 mM), or with both drugs combined, as indicated at a
fixed concentration ratio to perform median dose effect analyses for the determination of
synergy. Combination index (CI) values were determined. CI values less than 1 indicates
synergy, equal to 1 indicates additive interactions, and CI values > 1 indicates antagonism.
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Figure 4.6. Sorafenib and sodium valproate synergize in colony formation assays to
kill SW480 cells. SW480 cells were treated 12h after plating as single cells (250-1500
cells/well) in sextuplicate with vehicle (VEH, DMSO), sorafenib (Sor., 3.0-9.0 μM) or
sodium valproate (Val. 0.5-1.5 mM), or with both drugs combined, as indicated at a fixed
concentration ratio to perform median dose effect analyses for the determination of
synergy. Combination index (CI) values were determined. CI values less than 1 indicates
synergy, equal to 1 indicates additive interactions, and CI values > 1 indicates antagonism.
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Figure 4.7. Sorafenib and Vorinostat induce cell death in HCT116 wt and SW480
colon cancer cells. A, 3 µM sorafenib and 500 nM vorinostat treated continuously for 48
hours. B, 6 µM sorafenib and 500 nM vorinostat treated continuously for 48 hours. Cells
stained with Annexin V/propidium iodide and subjected to flow cytometry. Values
represent the means for three separate experiments ± SD. * p < 0.05, greater cell killing
than compared with any other treatment condition.
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Figure 4.8. Activation of ERK1/2 predicts for a Sorafenib and Vorinostat Response.
HCT116 cells (parental expressing K-RAS D13; deleted for K-RAS D12; deleted for KRAS D12 expressing H-RAS V12 and effector mutants of H-RAS V12), 24h after plating
in triplicate, were treated with vehicle (DMSO), sorafenib (3 μM), vorinostat (500 nM) or
sorafenib and vorinostat. Forty eight hours after exposure, cells were isolated and stained
with Annexin V –propidium iodide and cell viability determined by flow cytometry.
Values represent the means for three separate experiments ± SD. * p < 0.05, greater cell
killing than compared with any other treatment condition. Arrows indicate the RAF
mutant, V12 cells, and the parental gave significantly more cell death than the other
transfectants.
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Figure 4.9. Cell viability is slightly reduced in HT29 subclones by Sorafenib and
Vorinostat treatment. HT29 cells stably transfected with empty vector (HD6-4), K-RAS
V12 (HD6-V1), H-RAS V12 (H18), or K-RAS (HD6-G3), 24h after plating in triplicate,
were treated with vehicle (DMSO), sorafenib (3 μM), vorinostat (500 nM) or
sorafenib+vorinostat. Forty eight hours after exposure, cells were isolated and viability
determined via trypan blue exclusion assay. Values represent the means for three separate
experiments ± SD. * p < 0.05, greater cell killing than compared with any other treatment
condition.
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Figure 4.10. Sorafenib and Vorinostat decrease activation of ERK1/2 but not Akt in
HCT116 wt cells. HCT116 cells 24h after plating were treated with either vehicle
(DMSO) or with sorafenib (3 μM) and vorinostat (500 nM). 24 h – 96h after drug exposure
cells were isolated and subjected to SDS PAGE and immunoblotting to determine the
phosphorylation of ERK1/2 and Akt (S473). Data are from a representative of 3
independent studies.
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Figure 4.11 Activated MEK1 suppresses the toxicity of Sorafenib and Vorinostat. 3
HCT116 cells 24h after plating were infected with recombinant adenoviruses (empty
vector CMV; constitutively active MEK1 EE; constitutively active Akt) at a multiplicity of
infection of 25. Twenty four h after infection, cells were treated with vehicle (DMSO),
sorafenib (3 μM), vorinostat (500 nM) or both drugs together. Forty eight hours after
exposure, cells were isolated and stained with Annexin V – propidium iodide and cell
viability determined by flow cytometry. Values represent the means for three separate
experiments ± SD. * p < 0.05, greater cell killing than compared with any other treatment
condition. # p < 0.05, less cell killing than compared with parallel condition in vehicletreated cells.
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Figure 4.12. DNMEK1 increased Sorafenib and Vorinostat toxicity in HCT116 wt
cells. HCT116 cells 24h after plating were, as indicated, infected with recombinant
adenoviruses (empty vector CMV; dominant negative MEK1; dominant negative Akt) at a
multiplicity of infection of 25. Twenty four h after infection, cells were treated with
vehicle (DMSO), sorafenib (3 μM), vorinostat (500 nM) or both drugs together. Forty
eight hours after exposure, cells were isolated and stained with Annexin V – propidium
iodide and cell viability determined by flow cytometry. Values represent the means for
three separate experiments ± SD. * p < 0.05, greater cell killing than compared with any
other treatment condition. # p < 0.05, less cell killing than compared with parallel
condition in vehicle-treated cells.
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Figure 4.13. Sorafenib and Vorinostat increase the phosphorylation of p38 and JNK
in HCT116 wt cells. HCT116 cells 24h after plating were treated with either vehicle
(DMSO) or with sorafenib (3 μM) and vorinostat (500 nM). Six h or 24h after drug
exposure cells were isolated and subjected to SDS PAGE and immunoblotting to
determine the phosphorylation of JNK1/2 and p38. Data are from a representative of 3
independent studies.
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Figure 4.14. DNp38 or JNK IP did not suppress sorafenib and vorinostat lethality in
HCT116 wt cells. HCT116 cells 24h after plating were, as indicated, infected with
recombinant adenoviruses (empty vector CMV; dominant negative p38 MAPK) at a
multiplicity of infection of 25. Thirty minutes prior to drug exposure cells were treated as
indicated with vehicle (DMSO) or the JNK inhibitory peptide (JNK-IP, 10 μM). Twenty
four h after infection, cells were treated with vehicle (DMSO), sorafenib (3 μM),
vorinostat (500 nM) or both drugs together. Forty eight hours after exposure, cells were
isolated and stained with Annexin V – propidium iodide and cell viability determined by
flow cytometry. Values represent the means for three separate experiments ± SD. * p <
0.05, greater cell killing than compared with any other treatment condition.
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Figure 4.15. Overexpression of FLIP-s or ectopic expression of CrmA did not reduce
Sorafenib and Vorinostat lethality in HCT116 wt cells. HCT116 cells 24h after plating
were infected with recombinant adenoviruses (empty vector CMV; FLIP; CrmA) at a
multiplicity of infection of 25. Twenty four h after infection, cells were treated with
vehicle (DMSO), sorafenib (3 μM), vorinostat (500 nM) or both drugs together. Forty
eight hours after exposure, cells were isolated and stained with Annexin V – propidium
iodide and cell viability determined by flow cytometry. Values represent the means for
three separate experiments ± SD. * p < 0.05, greater cell killing than compared with any
other treatment condition.
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Figure 4.16. Drug lethality was blocked by overexpression of FLIP-s in SW480 cells.
SW480 cells 24h after plating were infected with recombinant adenoviruses (empty vector
CMV; FLIP) at a multiplicity of infection of 25. Twenty four h after infection, cells were
treated with vehicle (DMSO), sorafenib (6 μM), vorinostat (500 nM) or both drugs
together. Forty eight hours after exposure, the trypan blue exclusion assay was performed.
Values represent the means for three separate experiments ± SD. * p < 0.05, greater cell
killing than compared with any other treatment condition. # p < 0.05, less cell killing than
compared with parallel condition in vehicle-treated cells.
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Figure 4.17 Overexpression of XIAP did not reduce sorafenib and vorinostat lethality
in HCT116 wt cells, but overexpresion of Bcl-xL or DNCaspase 9 did reduce the toxic
effects of combination treatment. HCT116 cells were infected with recombinant
adenoviruses (empty vector CMV; caspase inhibitor XIAP; dominant negative caspase 9;
Bcl-xL) at a multiplicity of infection of 25. Twenty four h after infection, cells were treated
with vehicle (DMSO), sorafenib (3 μM), vorinostat (500 nM) or both drugs together. Forty
eight hours after exposure, cells were isolated and stained with Annexin V– propidium
iodide and cell viability determined by flow cytometry. Values represent the means for
three separate experiments ± SD. * p < 0.05, greater cell killing than compared with any
other treatment condition. # p < 0.05, less cell killing than compared with parallel
condition in vehicle-treated cells.
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Figure 4.18. Antiapoptotic and Proapoptotic protein expression during Sorafenib and
Vorinostat combination response. HCT116 cells 24h after plating were treated with
vehicle (DMSO), sorafenib (3 μM), vorinostat (500 nM) or both drugs combined. Cells
were isolated 6h and 24h after drug treatment and lysates subjected to SDS PAGE and
immunoblotting against the proteins indicated in the Figure panel. Blot shown is a
representation of two independent experiments.
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Figure 4.19. BCL-2/Bcl-xL/MCL-1 inhibitor GX15-070 (Obatoclax) increases cell
death in HCT116 wt cells. HCT116 cells 24h after plating in triplicate, were treated with
vehicle (DMSO) or GX15-070 (100 nM) followed by vehicle (DMSO), sorafenib (3 μM),
sodium valproate (1.0 mM) or sorafenib and valproate. Twenty four h and 48h after
exposure, cells were isolated and viability determined via trypan blue exclusion assay.
Values represent the means for three separate experiments ± SD. * p < 0.05, greater cell
killing than compared with any other treatment condition.
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Figure 4.20. BCL-2/Bcl-xL/MCL-1 inhibitor GX15-070 (Obatoclax) increases cell
death in SW480 cells. SW480 cells 24h after plating in triplicate, were treated with
vehicle (DMSO) or GX15-070 (100 nM) followed by, vehicle (DMSO), sorafenib (6 μM),
sodium valproate (1.0 mM) or sorafenib and valproate. Twenty four h and 48h after
exposure, cells were isolated and viability determined via trypan blue exclusion assay.
Values represent the means for three separate experiments ± SD. * p < 0.05, greater cell
killing than compared with any other treatment condition.
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Figure 4.21. HCT116 wt cells mount a death response to Sorafenib and Vorinostat
that is Fas-independent; however, SW480 cells have a Fas-dependent mechanism.
HCT116 or SW480 cells were transfected with siRNA molecules to knock down CD95 or
scrambled siSCR control (20 nM). Twenty four h after infection or transfection, cells were
treated with vehicle (DMSO), sorafenib (3 μM, 6 μM for SW480) vorinostat (500 nM) or
both drugs together. Forty eight hours after exposure, cells were isolated and stained with
Annexin V – propidium iodide and cell viability determined by flow cytometry. Values
represent the means for three separate experiments ± SD. * p < 0.05, greater cell killing
than compared with any other treatment condition. # p < 0.05, less cell killing than
compared with any parallel condition in vehicle-treated cells.
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Figure 4.22. Knockdown of CD95 did not rescue cell killing by obatoclax. SW480
cells were transfected with siRNA molecules to knock down CD95 or scrambled siSCR
control (20 nM). Twenty four hours after transfection, cells were treated with vehicle,
(DMSO) or GX15-070 (100 nM) followed by, vehicle (DMSO), or sorafenib (6 μM) and
sodium valproate (1.0 mM). Forty eight hours after exposure, cells were isolated and
viability determined via trypan blue exclusion assay (± SEM, n = 2 independent studies).
* p < 0.05, greater cell killing than compared with any other treatment condition. # p <
0.05, less cell killing than compared with any parallel condition in vehicle-treated cells.
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Figure 4.23. Lack of Fas/CD95 surface expression in HCT116 wt cells and SW620
cells, but not in SW480 cells. A, HCT116, SW480 and SW620 cells were plated in 4 well
glass chamber slides and 24h after plating cells were treated with vehicle (DMSO) or 6μM
sorafenib (3 μM, HCT116) and vorinostat (500 nM). Cells were fixed and not
permeabilized 0-8h after drug exposure. Fixed cells were immuno-stained for plasma
membrane associated CD95 and visualized using an FITC conjugated secondary antibody.
Images are representatives from two separate studies. B, HCT116, SW480 and SW620
cells were plated and treated with 6 µM sorafenib (3 µM for HCT116 wt) and 500 nM
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vorinostat continuously for 48 hours. After drug exposure, the trypan blue exclusion assay
was performed. Values represent the means for three separate experiments ± SD * p < 0.05,
greater cell killing than compared with any other treatment condition. # p < 0.05, less cell
killing than compared with any parallel condition in vehicle-treated cells.
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Figure 4.24. DISC formation in HCT116 wt and SW480 cells. A, HCT116 cells 24h
after plating were treated with vehicle (DMSO) or with sorafenib (3 μM) and vorinostat
(500 nM). B, , SW480 cells 24h after plating were treated with vehicle (DMSO) or with
sorafenib (6 μM) and vorinostat (500 nM). Six h after treatment cells were lysed and CD95
immunoprecipitated. Immunoprecipitates were subjected to SDS PAGE and
immunoblotting. A representative CD95 immunoprecipitate is shown (n = 3).
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Figure 4.25. Sorafenib and vorinostat stimulate autophagy in the HCT116 wt cells. A,
HCT116 cells in 4 well chambered glass slides 24h after plating were transfected with
siRNA molecules to knock down expression of Atg5 or Beclin1, or with a siScramble
control (20 nM). In parallel, cells were co-transfected with a plasmid to express LC3-GFP.
Twenty four h after transfection, cells were treated with vehicle (DMSO), sorafenib (3
μM), vorinostat (500 nM) or both drugs combined. Six hours after drug exposure, cells
were visualized at 40X using an Axiovert 200 fluorescent microscope under fluorescent
light using the FITC filter. The mean number of autophagic vesicles per cell from random
fields of 40 cells were counted. * p < 0.05, greater vesicularization than compared with any
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other treatment condition. # p < 0.05, less cell vesicularization than compared with
parallel condition in vehicle-treated cells. B, representative microscopic images taken from
each of the treatment conditions. Inset Panel: siRNA treatment knocks down of Beclin1 or
Atg5 in HCT116 cells 24h after transfection.
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Figure 4.26. Knockdown of Beclin 1 expression enhanced Sorafenib and Vorinostat
toxicity. HCT116 cells 24h after plating were transfected with siRNA molecules to knock
down expression of Beclin 1, or with a siScramble control (20 nM). Twenty four h after
infection or transfection, cells were treated with vehicle (DMSO), sorafenib (3 μM),
vorinostat (500 nM) or both drugs together. Forty eight hours after exposure, cells were
isolated and stained with Annexin V – propidium iodide and cell viability determined by
flow cytometry. Values represent the means for three separate experiments ± SD. * p <
0.05, greater cell killing than compared with any other treatment condition. **, greater cell
killing than si-scramble parallel condition.
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Figure 4.27. Sorafenib and Vorinostat induce autophagy that is CD95 dependent in
HCT116 wt cells. A, HCT116 cells in 4 well chambered glass slides 24h after plating
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were transfected with siRNA molecules to knock down expression of CD95 or with a
siScramble control (20 nM). In parallel, cells were co-transfected with a plasmid to express
LC3-GFP. Twenty four h after transfection, cells were treated with vehicle (DMSO),
sorafenib (3 μM), vorinostat (500 nM) or both drugs combined. Six hours after drug
exposure, cells were visualized at 40X using an Axiovert 200 fluorescent microscope
under fluorescent light using the FITC filter. The mean number of autophagic vesicles per
cell from random fields of 40 cells were counted. * p < 0.05, greater vesicularization than
compared with any other treatment condition. # p < 0.05, less cell vesicularization than
compared with parallel condition in vehicle-treated cells. B, representative microscopic
images taken from each of the treatment conditions.
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Figure 4.28 Sorafenib and Vorinostat activated PERK but did not alter eif2α
phosphorylation in HCT116 wt cells. HCT116 cells 24h after plating were treated with
vehicle (DMSO), sorafenib (3 μM), vorinostat (500 nM) or both drugs combined. Cells
were isolated 6h and 24h after drug treatment and lysates subjected to SDS PAGE and
immunoblotting against the proteins indicated in the Figure panel. Blot shown is a
representation of two independent experiments.
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Figure 4.29. DnPERK suppresses Sorafenib and Vorinostat-stimulated autophagy in
HCT116 wt cells. HCT116 cells 24h after plating were transfected with either a vector
control plasmid (CMV) or a plasmid to express dominant negative PERK. In parallel, cells
were co-transfected with a plasmid to express LC3-GFP. Twenty four h after transfection,
cells were treated with vehicle (DMSO), sorafenib (3 μM), vorinostat (500 nM) or both
drugs combined. Six hours after drug exposure, cells were visualized at 40X using an
Axiovert 200 fluorescent microscope under fluorescent light using the FITC filter. The
mean number of autophagic vesicles per cell from random fields of 40 cells were counted.
* p < 0.05, greater vesicularization than compared with any other treatment condition. # p
< 0.05, less cell vesicularization than compared with parallel condition in vehicle-treated
cells. Inset panel: cells transfected with vector control plasmid (CMV) or a plasmid to
express dominant negative PERK (but not LC3-GFP) were isolated 6h after drug exposure
and lysates subjected to SDS PAGE and immunoblotting to determine LC3 expression and
processing.
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Figure 4.30. Activation of JNK1/2 is dependent on PERK. HCT116 cells 24h after
plating were transfected with either: a vector control plasmid (CMV) or a plasmid to
express dominant negative PERK; a scrambled siRNA (siSCR) or a siRNA to knock down
CD95 expression (20 nM). Twenty four h after infection, cells were treated with vehicle
(DMSO) or with sorafenib (3 μM) and vorinostat (500 nM). Six h after drug exposure cells
were isolated and lysates subjected to SDS PAGE and immunoblotting to determine the
phosphorylation status of PERK and of JNK1/2. Data are from a representative of 2-3
independent studies.
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Figure 4.31. Molecular Inhibition of JNK1/2 signaling blocked Sorafenib and
Vorinostat-stimulated autophagy. HCT116 cells 24h after plating in 8 well chamber
slides were transfected with a plasmid to express LC3-GFP. Thirty minutes prior to drug
exposure cells were treated as indicated with vehicle (DMSO) or the JNK inhibitory
peptide (JNK-IP, 10 μM). Twenty four h after infection, cells were treated with vehicle
(DMSO), sorafenib (3 μM), vorinostat (500 nM) or both drugs combined. Six h after drug
exposure cells were visualized at 40X using an Axiovert 200 fluorescent microscope under
fluorescent light using the FITC filter. The mean number of autophagic vesicles per cell
from random fields of 40 cells were counted. * p < 0.05, greater vesicularization than
compared with any other treatment condition. # p < 0.05, less cell vesicularization than
compared with parallel condition in vehicle-treated cells.
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Figure 4.32. Sorafenib and Vorinostat toxicity is acidic sphingomyelinase dependent.
SW480 cells 24h after plating were transfected with siRNA molecules to knock down
expression of acidic sphingomyelinase (ASMase) or LASS6, or transfected with scrambled
siRNA molecules. Twenty four h after transfection cells were treated with vehicle (DMSO)
or myriocin (1 μM) and after 30 min, cells then exposed to vehicle (DMSO), sorafenib (6
μM), vorinostat (500 nM) or both drugs combined. Forty eight hours after exposure, cells
were isolated and stained with trypan blue dye. * p < 0.05, greater cell killing than
compared with any other treatment condition. # p < 0.05, less cell killing than compared
with any parallel condition in vehicle-treated cells.
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Figure 4.33. CD95 activation is acidic sphingomyelinase dependent. SW480 cells 24h
after plating in 4 well chamber slides were transfected with siRNA molecules to knock
down expression of acidic sphingomyelinase (ASMase) or LASS6, or transfected with
scrambled siRNA molecules. 24 h later cells were exposed to vehicle (DMSO), sorafenib
(6 μM), vorinostat (500 nM) or both drugs combined. Cells were fixed 6h after exposure
and the amount of plasma membrane associated CD95 determined by
immunohistochemistry. * p < 0.05, value less amount of cell surface CD95 compared to
vehicle-treated conditions.
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Figure 4.34. Overexpression of LASS6 enhanced Sorafenib and Vorinostat-induced
CD95 activation and enhanced tumor cell killing in SW620 cells. A, SW620 cells stably
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transfected with either vector control plasmid of a plasmid to express LASS6, 24h after
plating, were exposed to vehicle (DMSO), sorafenib (6 μM), vorinostat (500 nM) or both
drugs combined. Forty eight hours after exposure, cells were isolated and stained with
trypan blue dye. * p < 0.05, greater cell killing than compared with any other treatment
condition. B, SW620 cells 24h after plating in 4 well chamber slides as above, and exposed
to vehicle (DMSO), sorafenib (6 μM), vorinostat (500 nM) or both drugs combined. Cells
were fixed 6h after exposure and the amount of plasma membrane associated CD95
determined by immunohistochemistry. * p < 0.05, value greater amount of cell surface
CD95 compared to vehicle-treated conditions.
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CHAPTER 5 DISCUSSION: Sorafenib and Vorinostat
Previous studies in our laboratory have shown that sorafenib and vorinostat interact
to kill pancreatic, renal, and hepatocellular cancer cells via a CD95 dependent mechanism
107, 108

. The present studies were designed to examine whether sorafenib and HDACIs

interact in a synergistic manner to cause cell death in colon cancer cells.
In short term cell viability assays, sorafenib and vorinostat caused an additive to
greater than additive increase in colon cancer cell death. However, colony formation assays
is deemed as the best in vitro measurements of the impact of tumor cell growth in vivo. In
long-term colony formation assays, sorafenib and vorinostat treatment synergized to kill
HCT116 wt and SW480 colon cancer cells with CI values of less than 0.70. DLD1 cells
have higher levels of AKT, a pro-survival protein, which could be one reason we did not
detect synergy with the drug combination in this cell line.
Sodium valproate is an anti-epileptic drug and mood stabilizer that has been
rediscovered as and HDACI. Recently, it has been shown that valproic acid may affect the
concentration of HDAC2 by inducing its proteasomal degradation

117

. Thus, we used

sorafenib and the more specific HDACI inhibitor sodium valproate and also found that this
combination synergized to kill colon cancer cells with values of less than 0.75.
Collectively, our findings in colon cancer cells with respect to sorafenib and HDACI
treatment are in general agreement with those in NSCLC, renal, liver, melanoma and
pancreatic cancer cells 107, 108.
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In agreement with the concept that reduced basal activity in the MEK1/2 and/or
PI3K pathways will reduce cellular tumorigenicity and diminish drug toxicity, we found
that the lethality of sorafenib or vorinostat, or the drug combination was suppressed by
deletion of K-RAS D13 from HCT116 cells. We then investigated the relative importance
of three of the best defined pathways downstream of RAS proteins that were likely to be
involved in controlling drug toxicity: Raf-MEK1/2 (H-RAS V12 S35); PI3K-Akt (H-RAS
V12 C40); RAL GDS (H-RAS V12 G37). We have recently published using these cells in
vitro and in vivo that activation of RAS predicted resistance to PI3K inhibitors even in the
presence of activating PI3K mutations or loss of PTEN, whereas H-RAS V12 (C40) –
induced single activation of PI3K predicted for sensitivity to PI3K inhibitors.

Expression

of H-RAS V12 but not point effector mutants of H-RAS V12 that activate PI3K-Akt (C40)
or RAL GDS (C37) restored the toxicity of sorafenib or vorinostat, and the drug
combination, to near those levels observed in wild type cells. Activation of the RAL GDS
pathway did not restore vorinostat lethality whereas activation of PI3K-Akt signaling did
not restore sorafenib toxicity. Based on the findings of our prior studies, this suggests that
inhibition of PI3K signaling would be a rational approach to potentiate sorafenib toxicity.
In contrast to data with other effector point mutants, expression of the mutant that elevates
Raf-MEK1/2 signaling enhanced both vorinostat and the combination of sorafenib and
vorinostat lethality above those in parental cells or cells expressing wild type H-RAS V12.
In parental HCT116 cells we noted that sorafenib and vorinostat treatment caused a
delayed inactivation of ERK1/2 that was essential for the toxic drug interaction. In HT29
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subclones, we found that active K-Ras mutant also enhanced drug lethality with the
combination treatment.
In several studies HDACI lethality was shown to be enhanced when ERK1/2
pathway signaling was inhibited using potent small molecule MEK1/2 inhibitors

118, 119

.

Expression of dominant negative MEK1, but not dominant negative Akt, enhanced the
toxicity of sorafenib, vorinostat, and sorafenib and vorinostat combination. It is likely that
DnAKT could protect cells by increasing the activation of JNK, which in turn allows for
increased expression of Beclin 1 and more autophagy. Autophagy is protective in these
cells.

In addition, overexpression of MEK1 suppressed the drug combination.

Collectively our data leads us to conclude that while inhibition of ERK1/2 signaling can
promote the toxicity of vorinostat and facilitate sorafenib and vorinostat killing, elevated
basal/tonic levels of ERK1/2 activity within colon cancer cells are also essential for
vorinostat toxicity as well as sorafenib and vorinostat combination toxicity.
In some cell types, the toxicity of vorinostat has been linked to activation of the
JNK pathway

120, 121

. In HCT116 cells we noted that vorinostat and sorafenib+vorinostat

exposure increased the phosphorylation of p38α/β MAPK as well as that of JNK1/2.
Expression of dominant negative p38α MAPK in HCT116 cells had no apparent impact on
tumor cell toxicity, in contrast to our recent studies using MEK1/2 inhibitors and 17AAG
122

. Signaling by the JNK pathway has been linked to growth promoting signals as well as

both pro- and anti-apoptotic regulation 123-125. Inhibition of JNK1/2 using a molecular tool
modestly enhanced sorafenib+vorinostat toxicity in HCT116 cells; our somewhat
surprising finding became more easily understood when we noted that activation of
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JNK1/2 was dependent on expression of CD95 and was blocked by expression of dominant
negative PERK.
Autophagy in cancer remains to be controversial, as its induction may mediate both
cell death and cell survival. Our studies in colon cancer cells indicate that inhibitors of
autophagy induce enhanced levels of cell death. In our prior studies combining sorafenib
and vorinostat in NSCLC, renal, liver, melanoma and pancreatic cancer cells cell killing
was PERK- and CD95 dependent and the induction of protective autophagy was also
PERK- and CD95 dependent

107, 108

. In HCT116 cells, although PERK was activated,

phosphorylation of eIF2α did not occur. Drug-induced eIF2α phosphorylation was
previously noted to be essential for translational repression of c-FLIP-s and Mcl-1 levels
and in HCT116 cells, the levels of neither c-FLIP-s nor Mcl-1 were suppressed after drug
treatment 107, 108. This data may explain why CD95-caspase 8 signaling was non-productive
in HCT116 cells. To our surprise we found that knock down of CD95 expression in
HCT116 cells increased cell killing. Over half of colon cancer patients have mutations in
the CD95 receptor. Thus, it is likely that HCT116 wt cells carry a mutation in the CD95
receptor, rendering it cytoprotective. However, we noted that drug exposure promoted a
protective form of autophagy that was CD95 dependent. This data confirms our prior work
and argues that in some cell types and under certain treatment conditions, CD95 signaling
promotes cell survival.
We have shown that bile acids can promote ligand independent, ASMase and
ceramide –dependent, activation of CD95 in primary hepatocytes and that generated both
toxic signals (caspase 8 and JNK1 activation) as well as protective signals (JNK2

122
activation

12, 123

The generation of ceramide has been shown by many groups to promote

ligand independent activation of several growth factor receptors via the localization /
clustering of these receptors and other signal facilitating proteins into lipid rich domains
126, 127

. In melanoma, renal and liver cancer cells, combined but not individual exposure to

sorafenib and vorinostat, caused rapid activation of CD95 that did not correlate with
altered expression or cleavage of FAS-L 107, 108.
In SW480 cells, sorafenib and vorinostat exposure activated CD95 as judged by
increased plasma membrane staining for CD95 as well as increased DISC formation in an
ASMase- and de novo –ceramide synthesis pathway dependent fashion. However, in
patient matched SW620 cells that have reduced LASS6 expression, CD95 activation was
not observed. Our prior analyses in sorafenib and vorinostat treated HEPG2 cells
demonstrated that loss of ASMase function reduced formation of C14 and C16 ceramide
species whereas inhibition of the de novo synthesis pathway suppressed generation of
multiple dihydro-ceramide species, particularly the C12 / C14 / C16 and C20 / C24 / C26
dihydro-ceramides. SW480 cells demonstrated protection from cell death when acidic
sphingomyelinase was knocked down or when the pharmacological inhibitor of the de
novo pathway, myriocin was used. The combination of both siAsmase and myriocin did
not reduce cell death to a greater extent however. This could be due to the compensation
of other sphingomyelinases such as neutral or alkaline. The six known ceramide synthase
proteins (LASS) are localized in the ER and different LASS proteins have been noted to
generate different chain length ceramide forms, with LASS5 and LASS6 being most
closely linked to the generation of C14 and C16 dihydro ceramide

128, 129

. In general

123
agreement with the hypothesis that LASS6 is a key player in the regulation of sorafenib
and vorinostat toxicity, knock down of LASS6 in SW480 cells suppressed drug-induced
CD95 activation whereas expression of LASS6 in SW620 cells enhanced drug-induced
CD95 activation and cell killing. Whether the activities of LASS proteins are regulated by
a combination of vorinostat-modulated protein acetylation and sorafenib-induced changes
in ROS and Ca2+ fluxes in the ER will need to be examined in future studies.
In conclusion, sorafenib and vorinostat interact to kill multiple colon cancer cell
types. Unlike tumor cell types previously examined, such as NSCLC, renal, liver,
melanoma and pancreatic cancer cells, cell killing occurs via CD95-dependent and CD95independent mechanisms. Though in all cell types examined thus far, the induction of
mitochondrial dysfunction and activation of the intrinsic pathway play central roles in drug
lethality.
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CHAPTER 6 INTRODUCTION: 17AAG AND PD184352
6.1 Pancreatic Cancer
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the
tissues of the pancreas. The pancreas is a large organ that lies horizontally behind the lower
part of the stomach and it secretes enzymes that aid in digestion and hormones (i.e. insulin)
that help regulate the metabolism of sugars. The digestive juices are produced by exocrine
pancreas cells and the hormones are produced by endocrine pancreas cells. About 95% of
pancreatic cancers begin in exocrine cells 130.
Pancreatic cancer typically spreads rapidly and is seldom detected in its early
stages, thus it is one of the deadliest of all the solid malignancies. The five year survival
rate is only 4%

131

. For those patients with localized disease and small cancers (<2 cm)

with no lymph node metastases and no extension beyond the capsule of the pancreas,
complete surgical resection can yield 5-year survival rates of 18% to 24%

132

. Nearly

34,000 patients die from pancreatic cancer, and it is the fourth leading cause of cancer
death in the United States 131.
6.2 Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), also called malignant hepatoma is cancer of the
liver. Most cases of hepatoma are secondary to cancers caused by viral hepatitis (20%),
primarily hepatitis B and C, or cirrhosis (80%). The most common cause for cirrhosis in
the United States is alcohol abuse. In the United States, it was estimated that there would
be 21,370 new cases diagnosed and 18,410 deaths due to this disease in 2008 131. There is
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also a distinct male preponderance among all ethnic groups in the United States. Although
this hepatoma is rare in the United States, it is one of the most common tumors worldwide.
It is the fourth most common cancer in the world. HCC is especially prevalent in parts of
Asia and Africa. The male preponderance is most marked among Chinese Americans, in
whom the annualized rate of HCC among men is 20.9 per 100,000 and among women 8.0
per 100,000 population. HCC is one of the deadliest cancers in China 133. One of the most
common risk factors is the production of aflatoxins in food. Aflatoxins, which are
mycotoxins formed by certain Aspergillus species, are a frequent contaminant of
improperly stored grains and nuts. In parts of Africa, the high incidence of HCC in
individuals may be related to ingestion of foods contaminated with aflatoxins 134.
Treatment options depend on the tumor size and staging, but the prognosis is
usually poor with hepatomas. Only 10-20% of hepatomas can be removed completely by
surgery. If the cancer is not removed completely, the survival rate is usually only about 3
to 6 months. Liver transplantation is also an option and may be curative for relatively small
tumors. However, even liver transplantation is not typically possible in most cases as early
diagnosis is somewhat rare. Most patients receive chemotherapy, precutaneous ethanol
injection, transcatheter arterial chemoembolization (TACE), or radiotherapy which may
relieve symptoms and prolong life but these procedures are not curative 135 .
6.6 Hsp90 inhibitors
The highly conserved N-terminal domain of hsp90 is the binding site for
geldanamycin (GA), an ansamycin drug which specifically targets hsp90

136

. GA inhibits

the hsp90 ATPase with nanomolar affinity. This drug occupies the nucleotide-binding
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cleft within in the N-terminal domain 68. Radicicol is a macrocyclic antifungal structurally
unrelated to GA but posses the same function as GA. Radicicol can compete with GA for
the N-terminal domain of hsp90

137

. Thus, both of these inhibitors act like nucleotide

mimetics that lock hsp90 in an ADP-bound state. A major consequence of this action is
inhibition of p23-hsp90 interaction

138

. Like many chemotherapeutic agents, GA has a

dose-dependent selectivity for tumor cells. In cancer cells, Hsp90 has a higher affinity for
N-terminal ligands than in normal cells

139

. Thus, GA would preferentially target cancer

cells rather than normal cells since it binds the N-terminus of hsp90. GA however was
found to be too toxic for clinical development

140

.

Its derivative, 17-allylamino-17-

demethoxygeldanamycin (17-AAG), a reversible Hsp90 inhibitor, as well as the more
water-soluble compound 17-dimethoxygeldanamycin (17-DMAG) posses anti-tumor
activity and is currently undergoing clinical phase I trials. However, 17-AAG seems to
undergo extensive metabolism that can result in the generation of toxic species

141

(Figure

6.1).
6.7 PD184352 (CI-1040)
PD184352 is a second generation MEK1/2 inhibitor with enhanced bioavailability
(Figure 6.2). This drug does not compete with ATP for the binding site, thus PD184352
acts as an allosteric inhibitor, binding outside the ATP and ERK1/2 binding sites on
MEK1/2. PD184352 inhibits activation of MEK1 in cells by 50% at 2nM, a concentration
over 100 fold lower than that which inhibits MEK 1 activity in vitro. This drug is also
highly specific for MEK 1 and 2.

When given orally every 12 hours for 2 weeks,
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PD184352 exhibits a growth inhibitory effect on human colon tumor xenografts in mice.
This drug also decreases invasiveness and motility of HT29 cells 142.
6.8 Basis for 17AAG and PD184352 Project
We recently published that 17AAG and PD184352 interact to kill in hepatoma cells
via activation of the CD95 extrinsic apoptotic pathway 122. The present studies determined
whether the same killing mechanisms apply after 17AAG and PD184352 treatment in
colon cancer cells. Additional studies were designed to mechanistically advance our
knowledge of 17AAG and PD184352 in pancreatic and hepatoma cell lines.
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Figure 6.1. Chemical Structure of 17-allylamino-17-demethoxygeldanamycin
.
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Figure 6.2. Chemical Structure of PD184352 (CI-1040) 142.
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CHAPTER 7 MATERIALS AND METHODS: 17AAG AND PD184352
7.1 Materials
Dulbecco’s Modified Eagle’s Medium (DMEM), RPMI 1640 medium, Minimum
Essential Medium Alpha (MEMα), sodium bicarbonate, trypsin-EDTA, and penicillinstreptomycin were purchased from GIBCOBRL (GIBCOBRL Life Technologies, Grand
Island, NY. Minimum Essential Medium (MEM), Non-essential amino acids (NEAA) and
sodium pyruvate were from Cellgro (Herndon, VA). Trypan blue solution, formaldehyde,
acetic acid, 6-Diamidino-2-Phenylidole (DAPI), and dimethyl sulfoxide (DMSO) were all
obtained from Sigma Chemical (St. Louis, MO).
17AAG was supplied by Calbiochem (San Diego, CA) as a powder, dissolved in
sterile DMSO, and stored frozen under light-protected conditions at -80˚C. PD184352 was
purchased from Upstate Biotechnology (Lake Placid, NY).
Anti-Beclin-1 (60 kDa, 1:1000, rabbit polyclonal), phospho-/total-p38α/β (38 kDa,
1:1000, rabbit polyclonal), phospho-/total-JNK1/2 (46, 54 kDa, 1:1000, rabbit polyclonal),
anti-Bcl-xL (30 kDa, 1:1000, rabbit polyclonal), anti-FAS receptor (48 kDa, 1:1000, rabbit
polyclonal), were obtained from Cell Signaling Technology ( Worcester, MA). AntiGAPDH (37 kDa, 1:1000, mouse monoclonal), phospho-PERK (125 kDa, 1:500, rabbit
polyclonal), phospho-/total ERK1/2 (42, 44 kDa, 1:1000, mouse monoclonal), phospho/total-Akt (60 kDa, 1:1000, rabbit polyclonal), phospho-MEK and all of the secondary
antibodies (anti-rabbit-HRP, anti-mouse-HRP, and anti-goat-HRP) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Commercially available siRNA duplexes to
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knockdown RNA/protein levels were from Qiagen (Valencia, Ca): CD95 (SI02654463),
Beclin-1 (SI00055573).
7.2 Cell Culture
HCT116 (p53 wild type) cells are a colon cancer cell line from ATCC. HCT116 stably
transfected cell lines were previously generated. Cell lines were maintained in DMEM
medium with L-glutamine and supplemented with 10% (v/v) fetal bovine serum and 2%
(v/v) penicillin/streptomycin according to supplier instructions. SW480 cells are from
ATCC.

These cells were maintained in RPMI medium with L-glutamine and

supplemented with 10% (v/v) fetal bovine serum and 2% (v/v) penicillin/streptomycin
according to supplier instructions. SW620 cells (ATCC), patient matched to SW480 cells
were maintained in DMEM with L-glutamine and supplemented with 10% (v/v) fetal
bovine serum and 2% (v/v) penicillin/streptomycin according to supplier instructions.
HEPG2 (hepatoma) and MiaPaCa2 (pancreatic), were purchased from ATCC as well. All
cells were routinely subcultured and maintained in a 10 % CO2/90 % air/37oC humidified
incubator. In addition, all cells were examined frequently for contamination with bacteria
or fungus by visual inspection.

Also, cells were routinely tested for mycoplasma

contamination. Cells were not cultured in reduced serum media during any study in this
manuscript.
7.3 Assessment of Cell Viability
A method used for evaluating cell viability involves the trypan blue
inclusion/exclusion of isolated cells under light microscopy and scoring the percentage of
cells exhibiting blue staining indicative of cell death. Cells were washed once with PBS
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and trypsinized to detach cells from 12 well plates. Cells were centrifuged for 4 minutes at
1400 rpm at 25º C (room temperature). The media was then aspirated off and trypan blue
was added to the tube depending on pellet size. The trypan blue inclusion/exclusion
represents the integrity of the cellular membrane in that healthy, viable cells contain intact
cell membranes and thus reject the trypan blue stain, while damaged cells exhibit a blue
color due to a compromised cellular membrane that allows the trypan blue stain to be
incorporated into the cell. Viable cells and trypan blue stained cells were counted in a
hemacytometer viewed under a microscope. Calculations of cell death were made using the
number of trypan blue positive cells divided by alive cell number multiplied by 100 to get
the percentage of cell death.
7.4 Western Blot Analysis for Protein Expression
a.) Protein Isolation
Cells were plated at an appropriate density and treated with drug. At the indicated times
after drug exposure, cells were washed in PBS and then scraped from the using whole-cell
lysis buffer (0.5 M Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) βmercaptoethanol, 0.02% (w/v) bromophenol blue). A 1:20 dilution of protease inhibitor
cocktail (Roche) and a 1:100 dilution of phosphatase inhibitor cocktail (Roche) was also
added to the lysis buffer. The samples were then vortexed to dislodge the pellet, heated at
95-100 ºC for 5 minutes and placed immediately on ice.
b.) Electrophoresis
50-100 µg aliquots of cell protein (depending on the protein analyzed) were loaded onto a
polyacrylamide gel (10-15%, depending on the size of the protein analyzed). Samples
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were run in a SDS-PAGE running buffer (3.02g Tris-base, 14.40g glycine, 1.0g SDS, QS
to 1 L deionized water) for approximately 6 hours with a constant current of 60 mA.
Proteins were transferred onto a nitrocellulose membrane electrophoretically for 4 hours on
ice at 450 mA in transfer buffer (5.8g Tris-base, 2.9 g glycine, milli-Q water to 800 ml, 1.8
ml 20% (w/v) SDS, 200 ml methanol.)
c.) Immunoblotting
The membrane was blocked in TBS-tween buffer containing 5% (w/v) non-fat dry milk for
30 minutes. After removal of the blocking solution, the primary antibody was added at a
certain dilution to fresh block solution.

After an overnight exposure with the primary

antibody at 4ºC with orbital shaking, the antibody/wash solution was removed and the
membrane was washed with blotto wash (5 x 5 minutes).

The membrane was then

incubated with the corresponding goat anti-mouse or rabbit secondary antibody for 2 hours
at room temperature with orbital shaking. The secondary antibody was then removed and
the membrane washed in blotto wash again, 5 x 5 minutes.

All immunoblots were

visualized by ECL. For presentation, immunoblots were digitally scanned at 600 dpi using
Adobe PhotoShop CS2, and their color removed and Figures generated in Microsoft
PowerPoint.
7.5 Colony Formation Assay for Cell Survival
Cells were plated as single cells (100– 125 cells/well) in a 6 well plate. Twenty
four hours after plating, cells were treated with three different drug concentrations of each
drug as well as the combination of both drugs for 48 h. After 48 h, the drug-containing
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media was carefully removed, the cells were washed once, and fresh media lacking drugs
were added. Colony formation assays were cultured for an additional 10 to 14 days. Upon
colony formation, the medium was removed and the cells washed in 1X PBS. The cells
were then fixed on the dish by adding 100% methanol for 10 minutes. The methanol was
then removed and the cells were placed in a 0.1% (v/v) crystal violet (Sigma-Aldrich)
staining solution for 1 h. Colonies containing more than 50 cells were then counted and
normalized to the control cell survival sample. The survival data shown includes
individual assays performed at multiple dilutions with a total of six plates per data point,
repeated for a total of three experiments.
7.6 Recombinant Adenoviral Vectors: Infection in Vitro
We purchased recombinant adenoviruses to express (CrmA, c-FLIPs, Bcl-xL,
XIAP) or to express dominant negative (p38, caspase 9, or activated MEK1) as well as a
negative control using CMV (Vector Biolabs, Philadelphia, PA). In vitro adenoviral
infections were performed 24 hours after plating cells. Monolayer cultures were washed in
PBS prior to infection and specific virus was added to the monolayer cultures in serumfree growth medium at an m.o.i. (multiplicity of infection) of 25 (m.o.i. = # of virus per
cell).

The dishes were then placed on a rocker for 4 hours in a humidified atmosphere of

5% (v/v) CO2 at 37ºC. The serum free growth medium was removed after 4 hours and the
appropriate medium was added back to the cells and allowed to incubate overnight in the
same humidified atmosphere. The expression of the recombinant viral transgene was
allowed to occur for 24 h to ensure adequate expression of transduced gene products before
drug exposures.
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7.7 Transfection using Small Interfering RNA Molecules (siRNA) or plasmids
RNA interference or gene silencing for down-regulating the expression of specific
siRNA was performed using validated target sequences designed by Ambion (Austin, TX).
Plasmids were used at a concentration of 1 µg/µl or appropriate vector control plasmid
DNA. For transfection, 10 nM concentration of the annealed siRNA or the negative
control (a "scrambled" sequence with no significant homology to any known gene
sequences from mouse, rat, or human cell lines) were used. The siRNA molecules were
transfected into cells according to the manufacturer's instructions.
Briefly, cells were plated and allowed to sit overnight until about 80% confluent.
For each well 2 µl of siRNA was diluted in 100 µl pen-strep-and-FBS-free medium (100 µl
for chamber slides), in a 96 well plate. For each well, 2 µl of lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA) was diluted into 100 µl pen-strep-and-FBS-free medium in a
separate tube. The two solutions were incubated separately for approximately 5 minutes,
then combined and incubated at room temperature for 30 minutes. After incubation, the
total mix (400 µl) was added to each well. Cells were incubated for 4 hours at 37ºC with
gentle rocking. After 4 hours, the media was then replaced with 1 ml of its regular media
with antibiotics and FBS.
7.8 Immunohistochemistry: CD95 surface localization
Cells were plated on chamber slides, collected from the culture the next day, and
washed once with DPBS (Dulbecco’s PBS without calcium and magnesium, Mediatech,
Inc, Herndon, VA). The cells were then fixed in a solution of 4% paraformaldehyde in PBS
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for twenty minutes. Cells were washed again in DPBS and nonspecific binding was
blocked with a 1% (v/v) BSA and 2% (v/v) rat serum DPBS solution for 1 hour. Slides
were then incubated with a 1:100 dilution of the primary anti-Fas in block solution
overnight in a humidified chamber. The next day, slides were washed once in DPBS and
incubated for 1 hour with secondary goat anti-mouse Alexa 488/647 at a dilution of 1:500
in block solution. Slides were washed after an hour, and coverglasses were mounted onto
the glass slides using Vectashield with Dapi (Calbiochem, Madrid, Spain). Preparations
were observed in a Zeiss LCM 510 meta-confocal microscope and analyzed using the Axio
2.0 software. No labeling was observed when using the secondary antibodies alone.
7.9 Statistical Analyses
The effects of various treatments were analyzed using one-way ANOVA and a twotailed t test. Differences containing a p-value less than 0.05 were considered statistically
significant. The experiments shown are the means of multiple individual points (+/-SEM).
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CHAPTER 8 RESULTS: 17AAG and PD184352
8.1 17AAG and PD184352 decreases cell viability in HCT116 wt cells
HCT116 wt cells were plated at a density of 1x104 cells per well in a 12 well plate.
Cells were treated with vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or the
combination of both drugs. After 48 hours, the trypan blue exclusion assay was performed
as described in materials and methods. Treatment of the HCT116 wt cells resulted in a
greater than additive induction of cell killing than either individual agent alone (Figure
8.1).
8.2 17AAG and PD184352 synergize to kill HCT116 wt cells in colony formation
assays
We next used colony formation assays to determine long term effects on cell
survival. Colon cancer cells were plated as single cells (100-125 cells/well) in a 6 well
plate. There was one treatment condition per plate. Twenty four hours after plating, cells
were treated with either 17AAG (33, 66, 99 nM) or PD184352 (0.5, 1.0, 1.5 µM) and the
combination of both drugs as indicated at a fixed concentration ratio to perform median
dose effect analysis for the determination of synergy.

Forty eight hours after drug

exposure, the media was changed and the cells were cultured in drug free media for an
additional 10-14 days. Cells were fixed, stained with crystal violet, and colonies >50
cells/colony counted as described in materials and methods under colony formation assay.
Colony formation data was entered into the Calcusyn program and combination index (CI)
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values determined. CI values less than 1 indicates synergy, equal to 1 indicates additive
interactions, and CI values > 1 indicates antagonism (Figure 8.2 and 8.3).
8.3 Active Mutant Ral significantly sensitizes cells to 17AAG and PD184352
We next used RAS effector mutants to decipher the mechanism of action of this
drug combination. HCT116 wt, HCT116 V12, as well as the HCT116 V12 transfectants
were plated at a density of 1x104 cells per well in a 12 well plate. Cells were treated
vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or the combination of both drugs.
After 48 or 96 hours, the trypan blue exclusion assay was performed as described in
materials and methods. The RAL active mutant (HCT116-HRAS-V12-RAL) significantly
enhanced cell death at the 48 and 96 hour time points (Figure 8.4, 8.5).
8.4 DNp38 or JNK inhibitory peptide (JNK IP) does not significantly reduce cell
death in the HCT116 wt cells
Previous studies in our laboratory have shown that in hepatoma cells, the
combination of 17AAG and PD184352 induced rapid phosphorylation of p38 and no
relative changes in JNK activation
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. We tested whether inhibition of p38 or JNK

affected the cell death response with combination treatment. HCT116 wt and HCT116HRAS-V12-RAL cells were plated at a density of 2.5 x 104 in 12 well plates. Cells were
allowed to attach overnight and the next day cells were infected with adenovirus dominant
negative p38 (dnp38) or a CMV control adenovirus. Cells were infected as described in
materials and methods. The next day, cells were treated with vehicle (DMSO), 0.1 µM
17AAG, 0.5 µM PD184352, or the combination of both drugs. After 48 hours, the trypan
blue exclusion assay was performed as described in materials and methods. There was no
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significant difference among the HCT116 wt cells or the HCT116-HRAS-V12-RAL cells
in terms of p38 activity; p38 does not play a significant role in 17AAG and PD184352
lethality (Figure 8.6). In a separate experiment, cells were plated and treated with JNK IP
for two hours followed by vehicle (DMSO) or 0.1 µM 17AAG + 0.5 µM PD184352. The
JNK IP did not affect the lethality of the drug combination in the HCT116wt cells,
although there was an inhibitory effect with the HCT116-HRAS-V12-RAL cells (Figure
8.7).
8.5 Activated MEK1 suppresses the toxicity of 17AAG and PD184352
We next determined whether expression of constitutively activated MEK1
protected cells from 17AAG and PD184352 exposure. HCT116 wt cells and HCT116V12-RAL were plated at a density of 2.5x104 cells per well in a 12 well plate. Cells were
infected 24 hours after plating with empty vector control virus (CMV) or virus to express
constitutively active MEKEE (ca-MEKEE) as described in materials and methods. The
next day, cells were treated with vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or
the combination of both drugs. After 48 hours, the trypan blue exclusion assay was
performed as described in materials and methods. Activated MEK1 protected the cells
from the increase in cell death seen in the CMV control (Figure 8.8).
8.6 Protein expression of MAP Kinase members during 17AAG and PD184352
combination response
To further define the process of cell death, immunoblotting analysis in 17AAG and
PD184352 treated HCT116 wt and HCT116-HRAS-V12-RAL cells were performed. Cells
were plated at 1.0 x 106 in 10 cm dishes. Twenty four hours after plating, cells were
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treated with vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or the combination of
both drugs. Forty eight hours later, cells were isolated and western blot analysis was
performed as described in materials and methods. Many studies have argued that the
inhibition of the PI3K/Akt pathway is a key component in the toxicity of 17AGG rather
than RAF/MEK/ERK pathway

144, 145

, thus we analyzed the phosphorylation of Akt, p38,

ERK, and JNK. Unfortunately, p-Akt and p-p38 were undetectable and p-JNK remained
constant in cell lysates. The constant levels of JNK in the colon cancer cells correlated
with previous studies with hepatoma cells in which the JNK1/2 pathway was not activated.
The phosphorylation of p-ERK correlated with 17AAG and PD184352 toxicity (Figure
8.9).
8.7 17AAG and PD184352 induced CD95 activation in HCT116 wt cells
Based upon prior studies in which 17AAG and PD184352 induced CD95 activation
in hepatoma cells, we determined whether treatement of the drug combination elevated
CD95 plasma membrane levels (indicative of activation) in colon cancer cells. HCT116 wt
cells 24h after plating in 4 well chamber slides were exposed to vehicle (DMSO) or the
combination of 17AAG (0.1 µM) and PD184352 (0.5 µM). Cells were fixed 3-8h after
exposure and the amount of plasma membrane associated CD95 determined by
immunohistochemistry (± SEM, n = 2). HCT116 wt cells induced plasma membrane
CD95 activation (Figure 8.10).
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8.8 Overexpression of LASS6 enhanced 17AAG and PD184352 tumor cell killing in
SW620 cells
We determined whether expression of LASS6 in SW620 cells facilitated druginduced cell death. SW620 cells were stably transfected with either vector control plasmid
of a plasmid to express LASS6. Twenty four hours after plating, cells were exposed to
vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or both drugs combined. Forty eight
hours after exposure, cells were isolated and stained with trypan blue dye and cell viability
determined by visible light microscopy (± SEM, n = 2). Overexpression of LASS6 in
SW620 cells enhanced the toxicity of the drug combination (Figure 8.11). Collectively,
this data argues that activation of enzymes within the de novo ceramide pathway represents
a key step in the toxic actions of 17AAG and PD184253 in pancreatic cancer cells.
8.9 Overexpression of LASS6 enhanced 17AAG and PD184352-induced CD95
activation
We determined whether expression of LASS6 in SW620 cells facilitated druginduced CD95 activation. SW620 cells were stably transfected with either vector control
plasmid of a plasmid to express LASS6. SW620 cells 24h after plating in 4 well chamber
slides were exposed to vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or both
drugs combined. Cells were fixed 3-8h after exposure and the amount of plasma membrane
associated CD95 determined by immunohistochemistry (± SEM, n = 2). Overexpression of
LASS6 increased activation of CD95 (Figure 8.12).
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8.10 c-FLIP and CrmA significantly reduced lethality in MiaPaca2 cells
We decided to direct our attention to the mechanisms of drug toxicity in pancreatic
cells. Previous studies in our laboratory have shown that overexpression of c-FLIP-s
abolished lethality in 17AAG and PD184352 combination treatment in hepatoma cell lines
122

. Thus we decided to review this in MiaPaca2 cells. Cells were plated at a density of 2.5

x 104 in 12 well plates. Cells were allowed to attach overnight and the next day cells were
infected with adenovirus FLIP, cytokine response modifier A (CrmA), as well a CMV
control adenovirus. Cells were infected as described in materials and method. The next
day, cells were treated with vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or the
combination of both drugs. After 48 hours, trypan blue exclusion assays were performed
as described in materials and methods. Overexpression of FLIP-s inhibited cell killing in
MiaPaca2 cells (Figure 8.13). CrmA also suppressed cell death. Total cell lysates were
analyzed by immunoblotting with anti-FLIP to assess the levels of expression of infected
Flip in both cell lines (Figure 8.13, inset).
8.11 Overexpression of Bcl-xL or DNCaspase 9 reduced the toxic effects of
combination treatment in MiaPaca2 cells
To further investigate the apoptotic pathway and its role in 17AAG and PD184352
combination treatment, we tested the effects of overexpression of Bcl-xL or DNcaspase 9
on 17AAG and PD184352 lethality. MiaPaca2 cells were plated at a density of 2.5 x 104 in
12 well plates. Cells were allowed to attach overnight and the next day cells were infected
with adenovirus dominant negative caspase 9 (DNcaspase 9), Bcl-xL, as well a CMV
control adenovirus. Cells were infected as described in materials and methods. The next
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day, cells were treated with vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or the
combination of both drugs. After 48 hours, the trypan blue exclusion assay was performed
as described in materials and methods.

Overexpression of Bcl-xL or expression of

dominant negative caspase 9 suppressed 17AAG+PD184352 toxicity in MiaPaca2 cells,
arguing that the drugs were using the intrinsic pathway to kill this tumor cell type (Figure
8.14). Total cell lysates were analyzed by immunoblotting with anti-Bcl-xL to assess the
levels of expression of infected Bcl-xL in both cell lines (Figure 8.14, inset).
8.12 MiaPaca2 cells demonstrate a Fas-dependent mechanism
Prior studies have demonstrated in hepatoma cells that 17AAG and PD184352
toxicity was dependent on activation of CD95

122

. We decided to test this in MiaPaca2

cells. Cells were plated at a density of 2.5 x 104 in 12 well plates. Cells were allowed to
attach overnight and the next day cells were transfected with siScramble, or knockdown of
CD95 (siCD95), a death receptor and part of the extrinsic apoptotic pathway. Cells were
transfected as described in materials and method. The next day, cells were treated with
vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or the combination of both drugs.
After 48 hours, the trypan blue exclusion assay was performed as described in materials
and methods. In MiaPaca2 cells, knockdown of CD95 decreased cell death compared to
Si-scramble group (Figure 8.15).
8.13 MiaPaca2 cells enhanced 17AAG and PD184352-induced CD95 activation
MiaPaca2 cells 24h after plating in 4 well chamber slides were exposed to vehicle
(DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or both drugs combined. Cells were fixed 38h after exposure and the amount of plasma membrane associated CD95 determined by
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immunohistochemistry (± SEM, n = 2), (Figure 8.16). MiaPaca2 cells increased plasma
membrane levels in a time-dependent fashion.
8.14 Knockdown of Beclin 1 expression enhanced 17AAG and PD184352 toxicity in
HepG2 cells
We decided to investigate the effect of knockdown beclin 1 on cell death in HepG2
cells. Cells were plated at a density of 2.5 x 104 in 12 well plates. Cells were allowed to
attach overnight and the next day cells were transfected with siScramble or knockdown of
beclin1 (si-beclin1). Cells were transfected as described in materials and methods. The
next day, cells were treated with vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or
the combination of both drugs.

After 48 hours, trypan blue exclusion assays were

performed as described in materials and methods. Knockdown of Beclin 1 increased cell
death, with knockdown of beclin 1 increasing the toxicity of PD184253 as well (Figure
8.17).
8.15 DnPERK protected HepG2 cells from 17AAG and PD18435 toxicity
We next determined whether knockdown of PERK function could alter 17AAG and
PD184352 lethality in hepatoma cells. Cells were plated at a density of 2.5 x 104 in 12
well plates. The next day, cells were transiently transfected with pcDNA or DnPERK as
described in materials and methods. The next day, cells were treated with vehicle (DMSO),
0.1 µM 17AAG, 0.5 µM PD184352, or the combination of both drugs. After 48 hours, the
trypan blue exclusion assay was performed as described in materials and methods.
DnPERK suppressed cell death as compared to the pcDNA control (Figure 8.18).
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Figure 8.1. 17AAG and PD184352 reduce cell viability in HCT116 cells. Colon cancer
cells were treated with 0.1µM 17AAG and 500 nM PD184352 continuously for 48 hours.
After drug exposure, the trypan blue exclusion assay was performed. Values represent the
means for three separate experiments ± SD. * p < 0.05, greater cell killing than compared
with any other treatment condition.
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Figure 8.2. 17AAG and PD184352 synergize to kill HCT116 wt cells in colony
formation assays. HCT116 wt cells were treated 12h after plating as single cells (2501500 cells/well) in sextuplicate with vehicle (DMSO), 17AAG (33, 66, 99 nM) or
PD184352 (0.5, 1.0, 1.5 µM), or with both drugs combined, as indicated at a fixed
concentration ratio to perform median dose effect analyses for the determination of
synergy. Combination index (CI) values were determined. CI values less than 1 indicates
synergy, equal to 1 indicates additive interactions, and CI values > 1 indicates antagonism.
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Figure 8.3. 17AAG and PD184352 synergize to kill HCT116-HRASV12-RAL cells in
colony formation assays. HCT116-HRASV12-RAL cells were treated 12h after plating as
single cells (250-1500 cells/well) in sextuplicate with vehicle (DMSO), 17AAG (33, 66, 99
nM) or PD184352 (0.5, 1.0, 1.5 µM), or with both drugs combined, as indicated at a fixed
concentration ratio to perform median dose effect analyses for the determination of
synergy. Combination index (CI) values were determined. CI values less than 1 indicates
synergy, equal to 1 indicates additive interactions, and CI values > 1 indicates antagonism.
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Figure 8.4. Active mutant HCT116-HRAS-V12-RAL significantly sensitizes cells to
17AAG and PD184352. HCT116 cells (parental expressing K-RAS D13; deleted for KRAS D12; deleted for K-RAS D13 expressing H-RAS V12 and effector mutants of H-RAS
V12), 24h after plating in triplicate, were treated with vehicle (DMSO), 17AAG ( 0.1 µM),
PD184352 (500 nM) or the combination of both drugs. Forty eight hours after exposure,
the trypan blue exclusion assay was performed. Values represent the means for three
separate experiments ± SD. * p < 0.05, greater cell killing than compared with any other
treatment condition. Arrows indicate the RAL mutant gave significantly more cell death
than the other transfectants.
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Figure 8.5. Active mutant HCT116-HRAS-V12-RAL significantly increases toxic
effects of 17AAG and PD184352. cells (parental expressing K-RAS D13; deleted for KRAS D12; deleted for K-RAS D13 expressing H-RAS V12 and effector mutants of H-RAS
V12), 24h after plating in triplicate, were treated with vehicle (DMSO), 17AAG ( 0.1 µM),
PD184352 (500 nM) or the combination of both drugs. Ninety six hours after exposure, the
trypan blue exclusion assay was performed. Values represent the means for three separate
experiments ± SD. * p < 0.05, greater cell killing than compared with any other treatment
condition. Arrows indicate the RAL mutant gave significantly more cell death than the
other transfectants.
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Figure 8.6 DNp38 did not significantly suppress 17AAG and PD184352 lethality in
HCT116 wt or HCT116-HRAS-V12-RAL cells. Cells 24h after plating were, infected
with recombinant adenoviruses (empty vector CMV; dominant negative p38 MAPK) at a
multiplicity of infection of 25. Twenty four h after infection, cells were treated with
vehicle (DMSO), 17AAG (0.1 µM), PD184352 (500 nM) or the combination of both
drugs. Forty eight hours after exposure, the trypan blue exclusion assay was performed.
Values represent the means for two separate experiments ± SD. * p < 0.05, greater cell
killing than compared with any other treatment condition.
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Figure 8.7 JNK IP did not significantly suppress 17AAG and PD184352 lethality in
HCT116 wt or HCT116-HRAS-V12-RAL cells. Cells 24h after plating were treated two
hours prior to drug exposure to vehicle (DMSO) or the JNK inhibitory peptide (JNK-IP, 10
μM). Cells were then treated with vehicle (DMSO), or 17AAG (0.1 µM) and PD184352
(500 nM). Forty eight hours after exposure, the trypan blue assay was performed. Values
represent the means for two separate experiments ± SD. # p < 0.05, less cell killing than
compared with any other treatment condition.
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Figure 8.8 Activated MEK1 suppresses the toxicity of 17AAG and PD184352.
HCT116 cells 24h after plating were infected with recombinant adenoviruses (empty
vector CMV; constitutively active MEK1 EE) at a multiplicity of infection of 25. Twenty
four h after infection, cells were treated with vehicle (DMSO), 17AAG (0.1 µM),
PD184352 (500 nM) or the combination of both drugs. Forty eight hours after exposure,
the trypan blue exclusion assay was performed. Values represent the means for two
separate experiments ± SD. * p < 0.05, greater cell killing than compared with any other
treatment condition. # p < 0.05, less cell killing than compared with any other treatment
condition.
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Figure 8.9. Protein expression of MAP Kinase members during 17AAG and
PD184352 combination response. HCT116 and HCT-RAL cells 24h after plating were
treated with vehicle (DMSO), 17AAG (0.1 µM), PD184352 (500 nM) or both drugs
combined. Cells were isolated 24h after drug treatment and lysates subjected to SDS
PAGE and immunoblotting against the proteins indicated in the Figure panel. Blot shown
is a representation of two independent experiments.
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1.0 ± 1.01

0.1 µM 17AAG and
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1.13 ± 0.91
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1.0 ± 0.56

2.36 ± 0.67*

Figure 8.10. Fas/CD95 surface expression in HCT116 wt cells. HCT116 cells were
plated in 4 well glass chamber slides and 24h after plating cells were treated with vehicle
(DMSO) or 0.1 µM 17AAG and 500 nM PD184352. Cells were fixed and not
permeabilized 0-8h after drug exposure. Fixed cells were immuno-stained for plasma
membrane associated CD95 and visualized using an FITC conjugated secondary antibody.
Images are representatives from two separate studies. * p < 0.05, value greater amount of
cell surface CD95 compared to vehicle-treated conditions.
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Figure 8.11. Overexpression of LASS6 enhanced 17AAG and PD184352 tumor cell
killing in SW620 cells. SW620 cells stably transfected with either vector control plasmid
of a plasmid to express LASS6, 24h after plating, were exposed to vehicle (DMSO),
17AAG ( 0.1 µM), PD184352 (500 nM) or the combination of both drugs. Forty eight
hours after exposure, cells were isolated and stained with trypan blue dye. * p < 0.05,
greater cell killing than compared with any other treatment condition. **, greater cell
killing than compared with SW620-GFP parallel condition.
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Figure 8.12. Overexpression of LASS6 enhanced 17AAG and PD184352-induced
CD95 activation. SW620 cells stably transfected with either vector control plasmid of a
plasmid to express LASS6, 24h after plating in 4 well chamber slide , cells were exposed
to vehicle (DMSO) or 0.1 µM 17AAG and 500 nM PD184352. Cells were fixed and not
permeabilized 0-8h after drug exposure. Fixed cells were immuno-stained for plasma
membrane associated CD95 and visualized using an FITC conjugated secondary antibody.
Images are representatives from two separate studies. * p < 0.05, value greater amount of
cell surface CD95 compared to vehicle-treated conditions.
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Figure 8.13. Overexpression of c-FLIP-s or ectopic expression of CrmA reduced
17AAG and PD184352 lethality in MiaPaca2 cells. MiaPaca2 cells 24h after plating
were infected with recombinant adenoviruses (empty vector CMV; FLIP; CrmA) at a
multiplicity of infection of 25. Twenty four h after infection, cells were treated with
vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or both drugs together. Forty eight
hours after exposure, the trypan blue exclusion assay was performed. Values represent the
means for three separate experiments ± SD. * p < 0.05, greater cell killing than compared
with any other treatment condition. # p < 0.05, less cell killing than compared with any
parallel condition in vehicle-treated cells.
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Figure 8.14. Overexpression of Bcl-xL or DNCaspase 9 reduced the toxic effects of
combination treatment in MiaPaca2 cells. MiaPaca2 cells were infected with
recombinant adenoviruses (empty vector CMV; dominant negative caspase 9; Bcl-xL) at a
multiplicity of infection of 25. Twenty four h after infection, cells were treated with
vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352 or both drugs together. Forty eight
hours after exposure, cells were isolated and the trypan blue exclusion assay was
performed. Values represent the means for two separate experiments ± SD. * p < 0.05,
greater cell killing than compared with any other treatment condition. # p < 0.05, less cell
killing than compared with parallel condition in vehicle-treated cells.

159

30

*

25

GAPDH

siScram

siCD95

20

#

15

10

scramble

Combo

PD

17AAG

Veh

Combo

Veh

0

PD

5

17AAG

Percentage cell death above vehicle

CD95

siCD95

Figure 8.15. MiaPaca2 cells demonstrate a Fas-dependent mechanism. MiaPaca2 cells
were transfected with siRNA molecules to knock down CD95 or scrambled siSCR control
(20 nM). Twenty four h after infection or transfection, cells were treated with vehicle
(DMSO), 0.1 µM 17AAG, 0.5 µM PD184352, or both drugs together. Forty eight hours
after exposure, cells were isolated and the trypan blue exclusion assay was performed.
Values represent the means for three separate experiments ± SD. * p < 0.05, greater cell
killing than compared with any other treatment condition. # p < 0.05, less cell killing than
compared with any parallel condition in vehicle-treated cells.
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Figure 8.16. 17AAG and PD184352 induced CD95 activation in MiaPaca 2 cells.
MiaPaca2 24h after plating in 4 well chamber slides, cells were exposed to vehicle
(DMSO), 0.1 µM 17AAG, 500 nM PD184352 or the combination of both drugs. Cells
were fixed and not permeabilized 0-8h after drug exposure. Fixed cells were immunostained for plasma membrane associated CD95 and visualized using an FITC conjugated
secondary antibody. Images are representatives from two separate studies. * p < 0.05, value
greater amount of cell surface CD95 compared to vehicle-treated conditions.
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Figure 8.17. Knockdown of Beclin 1 expression enhanced 17AAG and PD184352
toxicity in HepG2 cells. HepG2 cells 24h after plating were transfected with siRNA
molecules to knock down expression of Beclin1, or with a siScramble control (20 nM).
Twenty four h after infection or transfection, cells were treated with vehicle (DMSO), 0.1
µM 17AAG, 0.5 µM PD184352, or both drugs together. Forty eight hours after exposure,
cells were isolated and trypan blue exclusion assay was performed. Values represent the
means for three separate experiments ± SD. * p < 0.05, greater cell killing than compared
with any other treatment condition. **, greater cell killing than si-scramble parallel
condition.
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Figure 8.18. DnPERK protected HepG2 cells from 17AAG and PD18435 toxicity.
HepG2 cells 24h after plating were transfected with either a vector control plasmid (CMV)
or a plasmid to express dominant negative PERK. Twenty four h after infection or
transfection, cells were treated with vehicle (DMSO), 0.1 µM 17AAG, 0.5 µM PD184352,
or both drugs together. Forty eight hours after exposure, cells were isolated and trypan blue
exclusion assay was performed. Values represent the means for two separate experiments ±
SD. * p < 0.05, greater cell killing than compared with any other treatment condition. # p
< 0.05, less cell killing than compared with any parallel condition in vehicle-treated cells.
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CHAPTER 9 DISCUSSION: 17AAG and PD184352
Previous studies in our laboratory have shown that 17AAG and PD184352 interact
to kill hepatocellular cancer cells via a CD95 dependent mechanism

122, 145

. The present

studies were designed to examine whether 17AAG and PD184352 interact in a synergistic
manner to cause cell death in colon and pancreatic cancer cells.
In short term cell viability assays, 17AAG and PD184352 caused an additive to
greater than additive increase in colon cancer cell death. However, colony formation assays
is deemed as the best in vitro measurements of the impact of tumor cell growth in vivo. In
long-term colony formation assays, 17AAG and PD184352 treatment synergized to kill
colon cancer cells.

This data is in agreement with previous data in hepatoma and

pancreatic cancer cell lines 122.
We then used the HCT transfectants to better understand the pathways leading to
17AAG and PD184352 toxicity.

RAL guanine nucleotide dissociation stimulator

(RALGDS) is one of several known Ras-regulated guanine-nucleotide exchange factors, or
GEFs, that function by activating RAL A and B GTPases. RALGDS is a RAL-guaninenucleotide exchange factor (GEF) that converts inactive RAL GTPase (both A and B
isoforms) to its active GTP-bound state. RALGDS can directly interact with activated Ras,
linking the RAL and Ras pathways. RALGDS was shown to bind to the same domain of
the Ras-Raf interaction domain, and as such it acts as a sequestering inhibitor for the
activation of Raf by Ras

146

.

Thus, the HCT116-HRAS-V12-RAL effector mutant
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significantly stimulated 17AAG and PD184352 cell death. Since RAL is known to interact
with Raf and subsequently inhibit the Raf/MEK/ERK MAP kinase pathway, we infected
these cells with an adenovirus to express constitutively active MEK (caMEKEE) and
treated the cells with 17AAG and PD184352.

Cell death was partially blocked by

caMEKEE in HCT116-HRAS-V12-RAL cells. RAL is also known to activate the JNK
pathway; however the JNK inhibitory peptide only partially blocked 17AAG and
PD184352 cell death. HCT116-HRAS-V12-RAL cells have higher basal levels of JNK.
There is also more ERK1/2 activation in HCT116-HRAS-V12-RAL cells.

Additional

studies beyond the scope of this dissertation would be required to identify the mechanism
of cell killing in the HCT116-HRAS-V12-RAL cells.
As hepatoma cells have previously been identified to show that 17AAG and
PD184352 kill by activation of CD95 and suppression of c-FLIP-s, we investigated
whether this occurs in pancreatic cells. Overexpression of c-FLIP-s protected MiaPaca2
cells from 17AAG and PD184352 cells death. This indicates that treatment of these cancer
cells by this drug combination is via the extrinsic pathway involving caspase 8.
Overexpression of the mitochondrial protective protein BCL-xL or inhibition of caspase 9
also suppressed cell killing. This argues that while caspase 8 is needed to induce cell
death, the intrinsic pathway and release of cytochrome c is crucial to the toxicity of this
drug combination treatment.
As we have established in hepatoma cells the role of CD95 in 17AAG and
PD184352 lethality, we investigated the role of ER stress. PERK can sense an increase of
improper folded proteins within the ER 46. Indeed, loss of PERK suppressed the cell death
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response in hepatoma cells. This result further implicates ER stress as a mechanism by
which 17AAG and PD184352 induces cell killing.
In conclusion, 17AAG and PD184352 interact to kill multiple cancer cell types.
An active RAL mutant plays a significant role in the toxicity of this drug combination in
colon cancer cells.

Though in all cell types examined thus far, the activation of CD95

play a central role in drug lethality.
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CHAPTER 10 DISCUSSION: GENERAL
Pre-cancerous cells can be eliminated from the body by programmed cell death.
Unfortunately, a hallmark of most cancers is a defect in the normal programmed cell death
that enables pre-cancerous cells to survive, proliferate, and become malignant.
Because most traditional chemotherapeutics act by triggering programmed cell death, such
agents are frequently ineffective against tumors that lack a functional programmed cell
death mechanism. Such tumors are said to be chemotherapy-resistant. Resistance to
traditional drugs has been a major impediment to successful therapeutic outcomes for
human cancers 1.
Combination therapy (using two different drugs simultaneously to treat cancer) has
proven to be a useful new tool for cancer patients who are refractory to traditional
therapies. The new approach is based on the theory that one drug can be used to restore
the ability of cells to commit suicide and the second can actually trigger the process. In
projects, sorafenib+vorinostat or 17AAG+PD184352 we used a more specific inhibitor
(i.e. sorafenib and PD184352) plus a very broad targeted drug (i.e. vorinostat, 17AAG).
Sorafenib alone has been approved for the use in renal cell carcinoma

88

.

Vorinostat has been approved for the treatment of cutaneuous T cell lymphoma (CTCL)
106

.

Sorafenib and HDACIs target multiple overlapping pathways.

Sorafenib and

vorinostat is now in Phase I clinical trials. This combination has been shown to be
effective against CML cell lines in the laboratory 96. In our drug combinations, sorafenib
inhibits RAF, inhibiting the RAK/MEK/ERK MAP kinase pathway which promotes cell
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survival

5, 6

. As stated previously, many cancer patients have active RAS mutations which

induce constitutive activation of the RAF/MEK/ERK MAP kinase pathway

147

. Sorafenib

thus can inhibit this pathway (even in cancers that have RAS mutations) 15. Vorinostat can
be used in combination to actually trigger the apoptotic process. A large number of
cellular proteins are modified post-translationally by acetylation, leading to altered
structure or function. Thus, vorinostat can induce oxidative injury as well as increase the
expression of death receptors 105, 112. It is likely that in different tumor types, inhibition of
specific HDACs will alter distinct biological processes contributing to anti-cancer effects.
This concept is analogous to the use of protein kinase inhibitors as anti-cancer
therapeutics. Specific protein kinase inhibitors may directly affect specific types of human
cancer.
17AAG alters hsp90 function, thereby promoting the proteosomal degradation of
hsp90 client proteins such as AKT and Raf-1 67. PD184352 as a single agent does not alter
tumor cell growth in phase II trials

148

. In vitro studies in our laboratory have shown that

in chronic myelogenous leukemia cells, inhibitors of MEK1/2 enhanced 17AAG lethality
by promoting mitochondrial dysfunction leading to apoptosis 149.
Our in vitro studies conclude that the combination of sorafenib+vorinostat or
17AAG+PD184352 induces a significant amount of cell death in colon, hepatoma, and
pancreatic cancers, respectively. Future studies in animal models will provide further
implications for these drug combinations in vivo.
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